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Abstract 
Self-assembly is central to the formation of biological structures and has generated a 
number of synthetic structures, such as biomaterials and photonic devices with 
important physical properties. Self assembly is of fundamental importance to soft 
matter science and synthetic biology. For most colloidal and nanoscale particles, the 
self-assembly properties are defined by the isotropic interaction energy between the 
particles. However for biological macromolecules such as proteins, anisotropic 
interaction energies and multiple degrees of freedom dominate the behaviour, making 
predictability of solution behaviour and crystallization extremely complex. To probe 
the impact of anisotropic interactions on the self-assembly of proteins, we have created 
three double mutants of human γD-crystallin (an eye lens protein) for which the phase 
diagrams for the single mutants are known. In effect, these double mutants establish a 
competition between the influences of each individual amino acid substitution, each of 
which are known to significantly influence the phase behaviour of the protein. Hence, 
the degree to which the molecular anisotropy of the protein contributes to the 
behaviour of the double mutant can be robustly examined by measuring phase 
diagrams for the double mutant proteins. Protein phase diagrams establish the solution 
conditions in which protein condensed phases such as the dense liquid phase due to 
liquid-liquid phase separation, protein crystals, protein gels and physical states such as 
protein aggregates occur.  
In a series of double mutants, two distinct behaviours associated with each of the two 
single amino acids substitutions were incorporated into the same protein (1) propensity 
to crystallize and (2) inverted solubility. Each single mutant differs in either the 
position of equilibrium phase boundary or the kinetics associated with either aggregate 
or crystal formation.  
The first double mutant was the P23VR36S variant of HGD. The phase diagram for 
this double mutant revealed that the protein formed crystals with normal solubility at 
very low protein concentrations (less than 1mg/ml). These crystals had an equilibrium 
phase boundary identical to the R36S single mutant. Given that the inverted solubility 
associated with the P23V substitution only occurs for aggregates formed at 
significantly higher concentrations (greater than 10mg/ml), the behaviour of the double 
mutant in this case is consistent with the behaviour expected from these substitutions.  
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The second double mutant, P23TR36S, again incorporating an amino acid substitution 
associated with crystallization (R36S) and another associated with inverted solubility 
(P23T) had a more dramatic and complex phase behaviour. It formed two different 
crystal types with different morphologies and very significantly, each crystal type 
displayed different solubility behaviour. One crystal had normal solubility (rod-shaped 
crystals) and the second crystal had inverted solubility (rhombic-shaped crystals). This 
type of polymorphism in proteins is a rare occurrence, where the only solution 
condition change required to interchange between the two crystal forms is temperature. 
Since the P23T single mutant occurs at significantly lower concentrations than for the 
P23V single mutant, it was possible to obtain a mutant protein which displayed the two 
single mutant behaviours within the same protein. The phase diagram also revealed 
that the phase boundary lines for the two different crystal types were qualitatively 
consistent with the phase lines for the individual single mutants. Furthermore, the point 
at which the solubility lines for the two single mutant proteins overlap, co-existence of 
the two crystal forms is observed. High resolution X-ray crystallography data (2.2Ǻ 
and 1.2 Ǻ respectively) confirmed that the two crystal forms are polymorphs. 
Finally, the third double mutant, P23VR58H, exhibits condensed phases associated 
with both single mutant proteins. The R58H mutant is associated with increased 
propensity to crystallize, but the kinetics of crystal growth is much slower than for the 
R36S mutant. Therefore, it was possible to form large aggregates (like those for the 
P23V single mutant) before crystallization occurred. When crystallization did occur, it 
was on the surface of the aggregates and not in the bulk solution. The equilibrium 
solubility line measured for this protein represents the coexistence between protein 
monomers and the protein condensed phases (crystals + aggregates). This suggests, 
contrary to the accepted view, that the protein aggregates are as thermodynamically 
stable as the protein crystal. Kinetic studies on the growth of the protein aggregates 
and crystals show that the growth of the aggregates occurs by first order growth 
kinetics and that crystallization occurs independently of the initial aggregate growth. 
The formation of both condensed phases is independent, but kinetically controlled.  
These observations, using three double mutants of HGD are striking and are the first 
time that this approach has been used to examine the role that molecular anisotropy of 
the protein surface has on the formation of condensed protein phases. While HGD is 
an effective model to examine these interactions, the work has important implications 
for protein crystallization efforts in general and for industrial processes where high 
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concentration protein solutions are required such as in the food and biopharmaceutical 
industries, since anisotropic protein-protein interactions are particularly important in 
understanding these systems.  
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1.1 Self-assembly in soft matter systems 
Self-assembly occurs when individual building blocks spontaneously organize into 
ordered structures, driven mostly by thermodynamic forces (Jones, 2002). The concept 
of self-assembly originated in chemistry and the motivation was derived from the 
central importance of self-assembly in biology which includes synthesis of protein 
molecules from linear polypeptide strands that spontaneously fold into functional 
three-dimensional structures (Voet & Voet, 2011); spontaneous organization of lipid 
molecules into bilayer membranes (Jones & Chapman, 1995); formation of viral 
capsids (Casjens & King, 1975) and the formation of whole organisms from living 
cells by division, development and organization. Self-assembly has also found wide-
spread use in chemistry pertaining to crystallization, formation of membrane vesicles, 
surface adsorption and supramolecular chemistry (Lehn, 2004).  
1.1.1 Colloids as simple models for soft matter systems 
Colloids are sub-microscopic particles with dimensions ranging from tens of 
nanometers to a few microns (figure 1.1). When in the nanometer range, these particles 
are below the limits of detection of a simple optical microscope, and direct imaging 
and measurement of the size of nanoscale colloidal particles became possible only with 
the advent of the electron microscope (Everett, 1988).  
 
 
 
 
 
 
 
 
 
Figure 1.1: Pictorial representation of silica  colloidal particles in a dispersion medium, taken from 
(Shi et al., 2013). 
The size range is not rigid and has exceptions such as in emulsions and slurries for 
which particles are larger in size. In systems such as clay and thin films, the colloidal 
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range is restricted to only one dimension (Everett, 1988). Due to the high surface to 
volume ratio, interfacial surface chemistry plays an important role in determining the 
behaviour of colloidal particles and the overall thermodynamic properties of the 
system, particularly its free energy.  
1.1.2 Interaction potential: Intermolecular forces governing 
colloidal behaviour 
To understand the interactions between colloidal particles, it is important to understand 
the origin and nature of the intermolecular forces that govern colloidal interactions. 
The existence of attractive forces between non-polar molecules has been traced back to 
the classical work of van der Waals (1873), but their origin was only understood when 
London (1930) quantified attractive forces between fluctuating dipoles using quantum 
mechanics (Everett, 1988).     
These attractive forces increase in magnitude as the molecules approach each another 
and are related to one other as per equation 1.1, 
                                            
7r
A
F att

                                              1.1 
where the attractive force (F
att
) is inversely proportional to the seventh power of 
separation. The work done in separating a pair of molecules from a distance d to 
infinity is given by equation 1.2, 
                  
667 6
1
d
A
d
A
dr
r
AdrFW
dd
att  

                           1.2 
If the energy at infinite separation is zero, then the attractive potential energy (U
att
) 
between the pair of molecules at a separation distance d is given by equation 1.3 (Aʹ is 
the attractive van der Waals constant), 
                                     
6d
A
WU att

                                         1.3 
This attractive interaction potential is schematically shown as (a) in figure 1.2, 
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Figure 1.2: Interaction potential energy between two molecules at a distance d (a) van der Waals 
attraction, (b) steric repulsion and (c) net interaction potential, taken from (Everett, 1988). 
As a pair of molecules approaches each other, the energies of attraction become 
increasingly negative. However, as the pair of molecules approach to very close 
distances, their electron clouds in non-bonding orbitals begin to interact which gives 
rise to a repulsive force that becomes increasingly infinite as the electron clouds 
interpenetrate.  
Thus, the repulsive potential generated from the intermolecular potential between two 
interacting pair of molecules is represented by equation 1.4 (Bʹ is the repulsive Born 
constant), 
                                         
12d
B
U rep

                                                  1.4       
which is schematically shown as (b) in figure 1.2.           
The total interaction potential energy between a pair of molecules is the sum of the 
contributions from the attractive and the repulsive forces represented by equation 1.5 
and schematically shown as (c) in figure 1.2. 
                             
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The above representation is usually referred to as the Lennard-Jones potential. Instead 
of expressing the above equation in terms of parameters A
ʹ
 and B
ʹ
, it is convenient to 
express the free energy interaction potential in terms of the depth of the potential well 
ε and the distance at which the interaction potential is zero, r0 (equation 1.6); 
                                  





















6
0
12
04
d
r
d
r
U                                      1.6 
1.1.3 Interparticle forces in colloidal interactions 
1.1.3.1 Electrostatic forces: the electric double layer 
One of the most significant interparticle forces that exist between colloidal particles is 
the electrostatic force that arises due to electrically charged surfaces. Surfaces become 
electrically charged by a variety of mechanisms which include ionization of surface 
groups, differential solution of ions from the surface of a sparingly soluble crystal, 
isomorphous substitution, charged crystal surfaces and specific ion adsorption 
(Everett, 1988). In order to examine the effect of surface charges on the properties of 
colloids, the fundamental electrostatic theory (Coulomb’s law) is applied.  
 
 
 
 
 
 
Figure 1.3: Pictorial depiction of electrical double layer, taken from (nanoComposix Europe 2015).   
A charge cloud or ionic atmosphere is developed around the surface of a charged 
colloidal particle which is generally referred to as an electric double layer (figure 1.3). 
The electric double layer consists of charges (positive or negative) distributed on the 
surface of colloidal particles which is balanced by the total charge in the double layer 
comprising an excess of oppositely charged ions (counter-ions). The interaction 
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between the associated double layers surrounding the colloidal particles influences the 
interparticle interaction between colloidal particles i.e. electrostatic repulsion is 
introduced between two similarly charged colloidal particles when their ionic clouds 
approach each other. An important consequence of the electric double layer is charge 
screening or shielding, where long-range electrostatic repulsive forces are screened, 
resulting in a decrease in the repulsive forces and an increase in the attractive forces 
between charged molecules (James & McManus, 2012).  
1.1.3.2 Steric repulsion: the adsorbed or anchored layers 
Adsorbed layers can influence the van der Waals attractive forces and give rise to 
repulsion between particles. If an adsorbed layer (usually a polymer) is rigid and 
compact, the adsorbed layer has a tendency to prevent the centres of the colliding 
particles from coming closer than 2 (a + δ) where a is the radius of the particle and δ is 
the thickness of the adsorbed layer. These particles with an effective collision diameter 
2 (a + δ) may be regarded as hard spheres. Two situations may arise due to the 
collision of particles. If the properties of the surface layer are closely similar to the 
dispersion medium (the medium in which the colloidal particle is dispersed), the 
attraction between the colloidal particles for a given centre-to-centre distance is 
unaffected. Since the centre-to-centre distance cannot fall below 2 (a + δ), the 
attractive potential at contact is lower than for an uncoated particle (δ = 0) (figure 1.4 
(a)). If the properties of the surface layer are closely similar to the core material of the 
colloidal particle, the coated particle will have a greater attractive potential than for the 
uncoated particle (figure 1.4 (b)). The density of the adsorbed polymer layer also 
affects the interaction potential of the colloidal particle. The adsorbed polymer layer is 
not dense enough for the colloidal particle to behave as a hard sphere. These polymer 
chains of the adsorbed layer extend out into the dispersion medium and depending on 
its chemical similarity; it begins interacting with the dispersion medium resulting in an 
open surface structure. On collision with other colloidal particles dispersed in the 
medium, the polymer chains interpenetrate which will contribute to the entropic 
repulsion term of the interaction potential. In order to stabilize the colloidal system, 
this approach is exploited by preparing colloidal particles whose adsorbed surface 
layer is chemically similar to the dispersion medium and different to the particle itself 
(Everett, 1988).  
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Figure 1.4: Interaction potential curves (a) when the surface layer has closely similar properties to the 
dispersion medium and (b) when the surface layer has closely similar properties to the core material, 
taken from (Everett, 1988).   
1.1.4 Phase diagrams for simple and complex colloidal 
systems  
The simplest colloidal systems are hard spheres which neither attract nor repel at 
distances greater than the particle diameter. Their characteristic feature is that they 
cannot interpenetrate, due to which two hard spheres with a radius a when held at a 
centre separation distance r produces infinite repulsion if (r ≤ 2a) i.e. when their centre 
separation distance is less than twice the radius 2a and zero repulsion when (r ≥ 2a) 
(Chaikin & Lubensky, 2000). The only externally controlled parameter affecting the 
interaction potential is the overall density of spheres which is expressed in terms of its 
particle volume fraction ϕ.  
 
 
 
 
 
 
 
 
Figure 1.5: Equilibrium phase diagram for uniformly sized hard spheres, taken from (Cheng et al., 
2001). 
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When the colloidal suspension consists of large and small particles, the pressure from 
the small particles produces an attraction between the large particles. This is referred to 
as depletion force and is the possible cause of phase separation for colloidal particles 
immersed in a liquid of non-adsorbing polymers (Mao et al., 1995). The equilibrium 
phase behaviour for hard spheres is one-dimensional, controlled by the volume fraction 
of the system. For (ϕ ≤ 0.49), the hard spheres exist in a fluid state; for volume 
fractions in the range (0.54 ≤ ϕ≤ 0.74), the hard spheres enter a face-centred cubic 
(FCC) crystal state; for volume fractions in the range (0.49 ≤ ϕ≤ 0.54), the hard sphere 
system partitions into two co-existing phases, one a crystal state and the other a fluid 
state constituting an ergodic system; and for (ϕ ≈ 0.58), the hard spheres may avoid 
nucleation to form a kinetically arrested disordered state i.e. structurally similar to a 
liquid but resembles an amorphous glass (figure 1.5) (Sciortino, 2002, Pusey & Van 
Megen, 1986). The phase diagram obtained for hard spheres modelled using attractive 
Yukawa potentials and square-well potentials are applied to protein solutions using 
Mayer and McMillan’s treatment of solutions as gaseous suspensions (McQuarrie, 
1976). Once this approximation is made, the gas phase is identified with the uniformly 
dispersed protein liquid phase, the gas-liquid coexistence curve correlates with the 
liquid-liquid binodal and the sublimation line corresponds to the liquidus or solubility 
line. When attractive interactions are introduced in hard sphere systems, the phase 
diagram becomes rich and diverse giving rise to distinct liquid, gas phases (gas phase 
is effectively a dilute solution, not an actual gas phase) and a liquid-gas critical point 
(Anderson & Lekkerkerker, 2002). Purely attractive interparticle attractions introduce 
new parameters such as strength and range of the attraction giving rise to two-
dimensional phase diagrams. The first temperature-density phase diagrams for 
colloidal particles with a short-ranged attraction used hard spheres with attractive 
Yukawa potentials based on Monte Carlo simulations (Hagen & Frenkel, 1994).  
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Figure 1.6: Standard temperature-density phase diagram for hard spheres (diameter σ) with attractive 
Yukawa potentials (range δ) (left) and for hard spheres (range of interaction δ ≤ σ/7) (right), taken from 
(Muschol & Rosenberger, 1997).    
As shown in figure 1.6 (left), gas (G) is the most stable low-density phase at high 
temperatures. When the temperature is lowered, phase separation into coexisting gas 
and liquid (G+L) phases occur. As the density of the hard spheres is increased, the gas-
liquid (G+L) and the gas-solid (G+S) coexistence curves intersect at the triple point 
(TP). When the density of the hard spheres reaches a maximum, solidification occurs. 
This standard phase diagram of hard spheres with attractive interactions is altered 
when the range of the interaction δ is modified to about one-seventh of the particle 
hard core diameter σ (δ ≤ σ/7) and is analogous to the phase diagram for simple fluids 
(figure 1.6 (right)). On reducing the range of interactions, the triple point vanishes and 
the gas-liquid coexistence curve shifts to a metastable region beneath the gas-solid 
coexistence curve as shown in figure 1.6. A similar phase diagram was obtained when 
hard spheres were modelled using attractive square-well potentials for δ < 0.25σ 
(Asherie et al., 1996).  
1.1.5 Protein phase diagrams 
The thermodynamic forces driving the transition of a protein from one phase to 
another are a combination of processes occurring between protein-protein and protein-
solvent molecules (Dumetz, Chockla, et al., 2008). A protein phase diagram is a map 
which represents the state of a protein as a function of temperature, concentration and 
various solution conditions such as pH, ionic strength, salt concentration (Asherie, 
2004).  
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The thermodynamics of phase transitions in protein solutions are in many ways closer 
to the thermodynamics of phase transitions in colloidal solutions (Adams et al., 1998, 
Hagen & Frenkel, 1994, Asherie et al., 1996, Pusey & Van Megen, 1986, Van Megen 
& Underwood, 1993) than to those of small-molecule inorganic solutions.  
A globular protein is similar to a colloidal particle in many ways. There has been a 
great deal of experimental work done, measuring phase diagrams for colloidal particles 
and many of these phase transitions are also observed for globular protein solutions 
(Asherie, 2004, Muschol & Rosenberger, 1997). A certain number of proteins, 
including the gamma crystallins and lysozyme have been described as hard spheres 
with short-range, attractive interactions (Rosenbaum et al., 1996). Proteins such as α-
crystallins behave like hard spheres with electrostatic repulsions and weak attractive 
interactions (Xia et al., 1994). Early work in this area used simple isotropic models to 
describe proteins as spherical particles with short-range attractive interactions, which 
could explain certain features of protein phase diagrams such as liquid-liquid phase 
separation of globular proteins with attractive interactions (Lomakin, Asherie, et al., 
1996, Asherie et al., 1996, Rosenbaum et al., 1996, Poon, 1997, Rosenbaum & 
Zukoski, 1996). These isotropic models work well for proteins in certain contexts, for 
example, the changes in the phase behaviour of lysozyme with increasing salt 
concentration (Muschol & Rosenberger, 1997). However they do not quantitatively 
reproduce many of the features of protein phase diagrams, such as the width of the 
binodal line (liquid-liquid co-existence line) (Lomakin et al., 1999). Aeolotopic 
models with nonuniform, short-range interactions, have proved more useful in 
accurately describing protein phase behaviour (Lomakin et al., 1999) and many newer 
aeolotopic or “patchy” colloidal models have been developed since (Sear, 1999, 
Romano et al., 2010, Dorsaz et al., 2012).  
Taking into account all the experimental observations and theoretical predictions, a 
generic phase diagram for globular proteins has been postulated explaining the basic 
features of protein solutions. As displayed in figure 1.7, three zones have been 
identified; zone I is identified as the region for protein crystal growth and the shaded 
region in zone I represents pregelation clustering that can interfere with and interrupt 
protein crystal growth; zone II represents the metastable region of the phase diagram 
where liquid-liquid phase separation occurs; and zone III represents the gelation 
region. The gelation zone corresponds to a dynamically arrested state in which the 
solution forms a non-equilibrium state such as a gel or glass. 
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Figure 1.7: Generic phase diagram for proteins with normal solubility, taken from (Muschol & 
Rosenberger, 1997). 
The phase diagram shown in figure 1.7 applies to proteins with normal solubility. 
However, for proteins with inverted solubility the phase diagram is altered and is as 
shown in figure 1.8.  
                   
 
                 
 
 
 
 
 
 
 
 
  Figure 1.8: Generic phase diagram for proteins with inverted solubility, taken from (Muschol & 
Rosenberger, 1997). 
To summarize, the location of phase boundaries of various protein solutions depend on 
the solution conditions in which the protein is dissolved including pH, ionic strength, 
physical conditions such as temperatures and the specific chemistry on the surface of 
proteins. A typical protein phase diagram for proteins interacting via short range 
attraction consists of i) a liquidus or solubility line denoting the concentration of the 
monomeric protein solution in equilibrium with the condensed crystal/aggregate phase. 
ii) a liquid-liquid coexistence line (binodal) metastable to the liquidus or solubility line 
where the protein solution separates into two co-existing liquid phases of unequal 
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protein concentrations by temperature quenching the protein solution, one a protein 
rich phase and the other a protein poor phase. The different phases appear in a protein 
solution due to concentration fluctuations at temperatures less that the critical 
temperature for phase separation. iii) a spinodal line separating the biphasic region to a 
metastable and an unstable region, the spinodal decomposition develops due to decay 
in concentration fluctuations when the system is quenched into the unstable region and 
phase separation occurs spontaneously without an activation energy barrier as shown 
in figure 1.9 (Berland et al., 1992, Broide et al., 1991, Grigsby et al., 2001, Asherie et 
al., 1996).  
 
 
 
 
 
 
 
Figure 1.9: Hypothetical protein phase diagram in the temperature-density plane showing the different 
phases, taken from (Muschol & Rosenberger, 1995).  
The liquid-liquid co-existence line (binodal) is metastable with respect to the 
liquidus/solubility line due to the characteristic ranges of interaction between protein 
molecules in the metastable region of the phase diagram. In this region of the phase 
diagram, the ranges of all proteins interactions are less than one quarter of the protein 
diameter in solution (Lekkerkerker et al., 1992, Hagen & Frenkel, 1994, Rascón et al., 
1995, Daanoun et al., 1994, Asherie et al., 1996, Rosenbaum et al., 1996).Globular 
proteins, in general range in diameter from 3-15nm, and as such their inter-particle 
interactions are determined hydration and hydrophobic interactions which extend to a 
few water molecular diameters, roughly 10 Å (Leckband & Israelachvili, 2001, Paliwal 
et al., 2005, Kuehner et al., 1997),  ionic or other bridges that have an even shorter 
range of a few angstroms (McPherson & Cudney, 2006, Dumetz et al., 2007), van der 
Waals interactions, which extend to about the same distances as ionic bridges (Velev et 
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al., 1998, Song & Zhao, 2004) and the electrostatic range defined by the Debye length 
depends on the ionic strength of the protein solutions (Muschol & Rosenberger, 1995, 
Coen et al., 1996). This metastability has been observed in various protein solutions 
(Berland et al., 1992, Thomson et al., 1987, Broide et al., 1991, Broide et al., 1996, 
Muschol & Rosenberger, 1997) and in colloidal solutions (Verduin & Dhont, 1995, 
Ilett et al., 1995, Gast & Russel, 1998), but not in simple fluids where the interaction is 
long-rage (Zemansky & Dittman, 1997).             
During liquid-liquid phase separation in protein solutions, formation of the dense 
liquid phase is characterised by two phase lines, the co-existence line and the spinodal 
line. The liquid-liquid phase separation (binodal) is experimentally observed in protein 
solutions during the formation of dense liquid droplets (clouding) and on changing the 
temperature conditions these droplets then undergo dissolution into the protein solution 
(de-clouding) (Muschol & Rosenberger, 1997, Galkin & Vekilov, 2000) whereas the 
spinodal line is observed when the protein molecules are dynamically arrested and the 
dense liquid phase forms without the presence of a nucleation barrier (Thomson et al., 
1987, Shah et al., 2004). There is a specific point on the phase diagram for protein 
solutions where the binodal and the spinodal meet, also referred to as the critical point 
for liquid-liquid phase separation. The critical temperature (Tc) for a protein solution is 
also defined as the highest temperature at which the two liquid phases co-exist.  
If a particular protein solution of a certain composition forms more than one solid 
phase, each solid phase will exhibit a different solubility line. Lysozyme found in 
chicken egg white forms two different crystal morphologies; tetragonal and 
rhombohedral crystals both exhibiting normal solubility with a shift in the liquidus 
lines depending on the crystal type formed as shown in figure 1.10 (Vekilov, 2012). 
This indicates that solubility is a property of the solution-crystal equilibrium and not a 
property of the protein by itself. Protein solid phases can also exhibit two different 
types of solubility; normal solubility where the concentration of solution in 
equilibrium with the crystal phase decrease as the temperature is lowered favoring 
formation and growth of the crystal phase as in lysozyme and inverted solubility 
(retrograde solubility) where higher temperatures favor liquid-liquid phase separation 
and protein crystallization as in hemoglobin C (Feeling-Taylor et al., 1999, Vekilov, 
Feeling-Taylor, Petsev, et al., 2002).  
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Figure 1.10: Phase diagram for lysozyme in 0.05M sodium acetate (pH 4.5 and 4% NaCl) showing the 
liquid-liquid co-existence line (binodal), liquid-liquid spinodal line, liquidus or solubility lines for the 
different crystal types and the gelation line (taken from (Vekilov, 2012)).   
Besides liquid-liquid phase separation and protein crystallization, protein solutions at 
higher concentrations form protein gels at temperatures above the critical point for 
liquid-liquid phase separation (Muschol & Rosenberger, 1997, Galkin & Vekilov, 
2000) as indicted by the gelation line in figure 1.10.  The molecular mechanism of 
protein gel formation is not completely understood as yet. Some attribute it to 
additional long-rage forces (Noro et al., 1999, Sear, 1999, Kulkarni et al., 2003), 
others to nonuniform anisotropic short-range interactions (Fu et al., 2003). A recent 
hypothesis for protein gelation has been proposed that relates it to the formation of 
weak, limited-lifetime networks of protein molecules (Pan et al., 2009). 
1.1.5.1 Phase diagram approach for protein crystallization 
Protein crystallization is a phase transition phenomena that can be mapped onto a 
phase diagram (figure 1.11) (Chayen & Saridakis, 2008). In a typical protein 
crystallization phase diagram, there are four distinct regions: an undersaturated zone 
where proteins are fully dissolved and do not crystallize; a metastable zone of low 
supersaturation where protein crystals are stable and they grow, but no further 
nucleation occurs; a nucleation zone of moderate supersaturation where spontaneous 
nucleation will occur and a precipitation zone of very high supersaturation where the 
proteins will precipitate (Chayen et al., 1996, Chayen, 2005, Ducruix & Giegé, 1992). 
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Figure 1.11: Schematic representation of protein crystallization phase diagram as function of protein 
concentration and various adjustable parameters such as precipitant concentration, pH and 
temperature, taken from (Chayen & Saridakis, 2008).  
1.1.6 Self-assembly of anisotropically generated complex 
colloidal systems 
The ability to build materials from anisotropic colloids has generated huge interest in 
the field of soft matter science. Nanoparticles and colloids have been generated by 
particle synthesis to yield a broad variety of building blocks with different shapes, 
compositions, patterns and functionalities (Glotzer & Solomon, 2007). Association of 
nanoparticles and colloids towards the formation of complex structures can be driven 
by shape anisotropy (Jones et al., 2010, Jones et al., 2011, Sacanna & Pine, 2011), 
directional entropic force (Young et al., 2013) and surface functionalization (Kraft et 
al., 2012, Wang et al., 2013, Wang et al., 2012) of individual building blocks. Another 
emerging approach that has been adopted for self-assembly of nanoparticles and 
colloids is anisotropically decorating the surface of particles with synthetic organic or 
biological molecules (Glotzer, 2004, Manoharan, 2004, Bianchi et al., 2011, Breed, 
2007, Zhang & Glotzer, 2004). This biologically inspired self-assembly has been 
exploited for the self-assembly of nanoparticles and colloids into specific structures 
and working devices (Long et al., 2007, Bowden et al., 2001). 
DNA-functionalized colloids are one example of how biologically inspired self-
assembly can be used to create well defined assembled structures. The process of self-
assembly is initiated by coating the surface of colloidal nanoparticles with single 
stranded DNA (ssDNA). Using two particle types, each functionalised with 
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complementary single stranded DNA oligomers allows highly specific colloidal self-
assembly. A 3-strand system has also been used where a linker ssDNA sequence 
complementary to the ssDNA coating the particles allows particle bridging (figure 
1.12) (Geerts & Eiser, 2010). 
 
 
              
           
Figure 1.12: DNA driven self-assembly of colloidal particles, taken from (Geerts & Eiser, 2010).  
In addition, Alivisatos and co-workers have demonstrated that the distance between the 
DNA-nanoparticle self-assembled structures can be manipulated by the DNA 
sequences used (Alivisatos et al., 1996). Nature has designed numerous enzymes that 
specifically aid in cutting and joining DNA, hence, a wide variety of strands may be 
produced that would recognize its complementary counterparts and may assist the 
DNA-based self-assembly process. The work by Mirkin and Alivisatos emphasized the 
potential role of DNA in generating complex three-dimensional structures that can 
self-assemble in a controlled and reversible manner (Mirkin et al., 1996).    
Thus DNA-based self-assembly can generate one-, two- and three-dimensional 
structures that cannot be made through the assembly of spherical colloidal particles 
and more importantly, it is directional anisotropic interactions that have inspired the 
generation of these biologically relevant structures having wide applications in bio-
sensing/bio-recognition and DNA/RNA delivery into cells (Geerts & Eiser, 2010, Tan 
et al., 2013).  
1.2 Protein structure and self-assembly 
The concept of anisotropy is pivotal to the self-assembly of proteins (Derewenda, 
2011, Lomakin et al., 1999). Protein molecules have evolved to adopt a three-
dimensional functional structure under physiological conditions. Proteins are 
polymeric chains of amino acids covalently joined by peptide bonds, which give a 
protein its primary structure (figure 1.13). The primary structure of a protein is 
stabilized by peptide bond formation which is a class of covalent bond formed between 
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a carboxylic acid and an amino group on two neighbouring amino acid molecules by 
the potential loss of a water molecule as shown in figure 1.13. The peptide bond 
formed is planar due to the delocalization of electrons giving it a partial double bond 
character, which restricts conformational freedom and flexibility within the protein 
molecule. The 20 most commonly known amino acids that participate in peptide bond 
formation in proteins are sequentially arranged in the form of a linear chain with the 
amino acid sequence dictated by the nucleotides in the gene encoding it.  
 
 
 
 
 
 
 
Figure 1.13: Formation of a peptide bond between two amino acid units by condensation reaction, 
taken from (Russell, 2011).   
The primary polypeptide chain folds into α-helices or β-sheets formed through 
hydrogen-bonding interactions between N-H and C꞊O groups located in the invariant 
parts of the amino acids in the polypeptide backbone as shown in figure 1.14. The α-
helical structure is stabilized by hydrogen bonds formed between the hydrogen atom 
attached to the electronegative nitrogen atom of a peptide bond and the electronegative 
carbonyl oxygen atom on the amino-terminal end of another peptide bond that are 
spaced four residues apart while β-sheets are composed of two or more stretches of at 
least 5-10 amino acids folded and aligned alongside one another, stabilized by 
hydrogen bonds as shown in figure 1.14. The elements of the secondary structure of a 
protein i.e. α-helices and β-sheets along with the non-secondary structural elements 
such as loops and links fold into tertiary structures (figure 1.15). Many proteins also 
form quaternary structures by the association of folded chains of more than one 
polypeptide unit as shown in figure 1.15. Therefore, the formation of stable 
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tertiary/quaternary structures by the process of folding is one major natural self-
assembly process found in proteins.     
 
 
 
  
 
   
 
 
 
 
 
 
Figure 1.14: α-helix (left) and parallel β-sheet (right) secondary 
structural conformations of a protein, taken from (National 
Sciences Learning Centre, Washington University 2011).   
 
Figure 1.15: Tertiary (3°) (left) and quaternary (4°) (right) protein structures formed by protein 
folding, taken from (Petsko & Ringe, 2004). 
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1.2.1 Intermolecular self-assembly of proteins 
Proteins are divided into two major classes: globular proteins and transmembrane 
proteins. Globular proteins are water-soluble proteins that occur in the cytosol of living 
cells and body fluids, while transmembrane proteins are embedded in cellular 
membranes and serve to transmit signals across the membrane between the 
extracellular matrix and the cytosol. Transmembrane proteins occur as single 
molecules in the cellular membrane space, in some cases they self-assemble into 
complex two-dimensional structures that carry out specific functions (Byrne & Iwata, 
2002). In other cases, they self-assemble into two-dimensional crystals; the formation 
of two-dimensional crystals is mediated by the aggregation of these single molecules 
which can be compared to a phase transition phenomena, although poorly understood 
(Oesterhelt & Stoeckenius, 1973). Better understood are the phase transitions of 
globular proteins that result in the formation of several condensed phases such as 
dense liquid phase due to liquid-liquid phase separation, protein crystals and protein 
gels (Vekilov, 2010b).  
A change in the physical state of the protein also gives rise to solid phases i.e. 
amorphous or disordered protein aggregates (figure 1.16). A different class of protein 
solid phase known as amyloid fibrils can also be formed by condensation that is 
facilitated by the partial unfolding of an amyloidogenic protein or peptide chain into 
linear, one-dimensional and ordered/structured aggregates (Lomakin, Chung, et al., 
1996, Kelly, 1997, Finkelstein & Ptitsyn, 2002). These ordered aggregates are 
associated with the formation of neurodegenerative disorders such as Alzheimer’s and 
Parkinson’s diseases (Carver et al., 2002).  
Phase transitions of globular proteins do not affect the structural integrity of protein 
molecules and the thermodynamic forces or the kinetic pathways that result in the 
transition phases are not controlled by intermolecular dynamics (Vekilov, 2010b, 
2012). A detailed understanding about the physical laws that control these phase 
transitions and the fundamental mechanisms that drive them are essential to understand 
the formation of solid and dense-liquid condensed phases of compact, folded globular 
proteins.  
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Figure 1.16: Schematic representation of linear ordered aggregation (left) and disordered three-
dimensional amorphous aggregation (right), taken from (Stranks et al., 2009) .  
1.3 Protein condensation  
Protein condensation is a widely occurring phenomenon which has relevance in the 
following areas of study: 1. Protein condensation leading to the formation of diseases 
such as cataract, sickle cell anemia, Alzheimer’s etc. 2. Protein condensation leading to 
the formation of protein crystals have been widely used to obtain the three-dimensional 
atomic structure of protein molecules by X-ray crystallography. 3. Protein 
condensation leading to the formation of undesirable protein aggregates in bio-
pharmaceutical industries. These are discussed in detail below.         
1.3.1 Protein condensation diseases 
Protein condensation is a contributing factor during the pathogenesis of several 
diseases. Some of these include cataract, sickle cell disease and Alzheimer’s disease 
and are as described below. 
Cataract is a protein condensation disease, caused by opacity of the eye lens due to 
changes in its refractive index over distances comparable to the wavelength of 
transmitted light (Delaye & Tardieu, 1983, Benedek, 1971) (figure 1.17).  
 
 
 
 
 
 
 
Figure 1.17: Cataractous lens showing protein deposits taken from (Review of Optometry 2011).  
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The vertebrate lens is an avascular cellular structure which is mainly composed of 
highly elongated, terminally differentiated fiber cells (Bassnett et al., 2011, Kuszak et 
al., 2004) as shown in figure 1.18. Within the fiber cells, the α-, β- and γ-crystallins are 
the most abundantly found proteins. The total protein concentration in the nucleus of 
the eye lens exceeds 400 mg.ml
-1
 (Hejtmancik, 2008). The high concentration of the 
soluble crystallin proteins contributes to the high refractive index of the eye-lens 
(Slingsby et al., 2013, Wistow, 2012, Bloemendal et al., 2004), responsible for 
diffracting and concentrating light on the retinal cells.  
 
 
 
 
 
 
 
 Figure 1.18: Scanning electron microscopy image of eye lens fibre cells, taken from the (The Institute 
of Optics, University of Rochester). 
The γ-crystallins belong to a family of structurally homologous, monomeric proteins, 
expressed in mammalian lenses (Schoenmakers et al., 1984, Summers et al., 1984). 
The γ-crystallins in the eye lens are small, compact, globular, structural proteins with 
short-range order and together with α- and β-crystallins are important in maintaining 
the transparency and refractive index of the eye lens to produce clear focussed images 
on the light sensitive cells of the retina. However, it is the short-ranged attractive 
protein-protein interactions that differentiate the γ-crystallins from the α- and β-
crystallins (Tardieu et al., 1992). These attractive interactions within the eye lens 
reduces the osmotic pressure, but make the protein mixture more prone to phase 
separation and aggregation (Clark, 1994). In spite of this, γ-crystallins remain soluble 
at very high concentrations exceeding 400 mg.ml
-1
 with very little turn over (Zigler, 
1994). 
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There are two types of cataract that affect human populations worldwide. Genetically 
induced congenital/childhood cataracts, caused by single-point mutations in the 
crystallin proteins of the eye lens, where crystallin protein mutations result in the 
formation of protein condensed phases such as protein crystals (Pande et al., 2001) or 
protein aggregates (Pande et al., 2005) which significantly scatter light and cause mild 
to severe forms of opacity. The other is age-related cataract caused by increased 
susceptibility to environmental changes such as light, hyperglycaemic, osmotic, 
oxidative or other stresses (Hejtmancik et al., 2001). Certain post-translational 
chemical modifications such as proteolysis, intermolecular disulfide bridges, 
deamidation of asparagine and glutamine residues, racemization of aspartic acid 
residues, phosphorylation, non-enzymatic glycosylation and carbamylation 
(Hejtmancik et al., 2001) in the eye lens proteins result in the formation of protein 
aggregates associated with ageing lenses. The progression of a cataractogenic 
condition is characterized by increased lens turbidity and light scattering due to the 
formation of higher molecular weight aggregates. These protein aggregates may be 
held together by covalent forces such as disulfide and glycosidic linkages or non-
covalent forces such as hydrophobic, van der Waals, hydrophilic and electrostatic 
interactions.  
Sickle cell disease is a protein condensation disease caused by single-point mutation at 
the 6
th
 site in each of the two β-chains of the hemoglobin tetramer by substituting the 
hydrophilic, negatively-charged glutamatic acid residue with the hydrophobic, 
positively-charged valine residue (Ingram, 1956, Vekilov, 2007). Hemoglobin found in 
red blood cells, are globular proteins that carry oxygen (O2) and carbon dioxide (CO2) 
molecules throughout the body, each hemoglobin protein molecule comprises of four 
polypeptide chains, two identical α-chains and two identical β-chains held together by 
non-covalent interactions.  
A single-point mutation of the tetrameric hemoglobin protein results in the formation 
of hemoglobin S which alters the phase transition of the normal protein under 
deoxygenated conditions forming polymerized, helically twisted fibres (figure 1.19) 
that associate to form a gel phase (Bookchin & Nagel, 1981, Hirsch et al., 1985). The 
resulting fibrillar condensate causes distortion in the shape of red blood cells resulting 
in a sickle appearance which undergo reversible phase transition from gel phase into 
aqueous hemoglobin solution upon re-oxygenation (Eaton & Hofrichter, 1990). 
Homozygous CC disease is another example for a hemoglobin protein condensation 
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disease in red blood cells caused by a single-point mutation at the 6
th
 amino acid 
position of the β subunit that replaces negatively charged glutamate with a positively 
charged lysine (Hunt & Ingram, 1958). The single-point mutation results in the 
formation of protein crystals in vivo under oxygenated conditions (figure 1.19) (Hirsch 
et al., 1985, Lin et al., 1989, Feeling-Taylor et al., 2004), with a mild chronic 
hemolytic anemia (Lessin et al., 1969).  
 
 
 
 
 
 
 
 
Figure 1.19: Formation of aggregates or polymerized helically twisted fibres in hemoglobin S disease 
(left) taken from (Biology Learning Centre, The University of Arizona 2007) and protein crystals in 
hemoglobin C disease (right) taken from (Interim LSU Hospital). 
Alzheimer’s disease is a protein condensation disease formed by the association of the 
β-amyloid peptide (Aβ) into long fibrils that eventually form amyloid plaques. Both 
fibrils and plaques are somewhat neurotoxic, but more recent work has indicated that 
in fact smaller oligomeric forms of the protein are significantly more neurotoxic than 
the larger aggregates (Selkoe, 1994).  
 
 
 
 
 
Figure 1.20: Formation of Aβ fibrils during the pathogenesis of Alzheimer’s disease, taken from (The 
Scripps Research Institute). 
Aβ is a ~4 KDa protein comprising a common core sequence with heterogeneous N- 
and C- termini. The most common form of Aβ is 40 amino acids long referred to as 
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Aβ40. Aβ42, the lesser known component differing by the presence of two additional 
amino acids is also associated with the disease (Irvine et al., 2008). Aβ peptide is the 
product of enzymatic breakdown of a large membrane protein called amyloid precursor 
protein; APP. Alzheimer’s disease is characterized by a decrease in the concentration 
of Aβ monomer resulting in protein condensation due to the formation of Aβ 
oligomers and long protein fibrils (figure 1.20).    
1.3.2 Protein crystallization 
1.3.2.1 Understanding self-assembly of proteins leading to protein crystallization  
Understanding protein interactions in aqueous solutions is key to understanding the 
self-assembly of proteins into the formation of solid condensed phases such as protein 
crystals. The osmotic second virial coefficient, B22, is a thermodynamic parameter that 
has predominantly been used in the literature to characterise protein interactions 
arising from weak non-covalent interactions such as electrostatic repulsions, van der 
Waals attractions, hydrophobic and hydration forces (Zimm, 1946, Neal et al., 1998). 
George et al. have pointed out that negative B22 values correspond to attractive 
interactions that strongly correlated with the crystallization conditions for globular 
proteins (George et al., 1997). Another thermodynamic parameter that is used to 
characterise protein interactions is the kD (net interaction potential) values from QELS 
(Quasi-elastic light scattering) experiments (James & McManus, 2012), where 
negative kD (net interaction potential) values correspond to attractive interactions. 
While B22 and kD values are useful for some proteins such as lysozyme, it isn’t always 
a good predictor of protein solution behaviour.    
Proteins, in general are difficult to crystallize. One possible explanation is that 
polypeptide chains that make up a protein have significant amount of conformational 
entropy that affects crystallization properties of proteins (Doye et al., 2004). Thus, 
proteins have evolved not to crystallize because it compromises the viability of the 
cell. Secondly, proteins have directional interactions that may not be compatible with 
simple crystal lattices (Sear, 1999). Thirdly, formation of kinetically trapped phases 
such as aggregates and gels are enhanced by directional, anisotropic interactions which 
suppress the nucleation of protein crystals (Muschol & Rosenberger, 1997, Lomakin et 
al., 1999, Romano et al., 2010).    
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In order to obtain diffraction quality protein crystals, the protein molecule must be 
immobilized in a lattice structure with limited dynamic motion. Several physical 
techniques have been employed to encourage protein crystallization by controlling 
conditions such as temperature, pH and the addition of chemical excipients to achieve 
supersaturation, a non-equilibrium condition that favors the spontaneous appearance of 
a new phase. Protein crystallization is a first-order phase transition that occurs via 
nucleation and growth of the critical nuclei into large single crystals. The first and 
most important pre-requisite for protein crystallization is nucleation. If the 
concentration of the protein solution lies near to the metastable critical point on the 
phase diagram for the protein, concentration fluctuations that leads to separation of the 
protein into protein-rich and protein-poor phases enhance protein crystal nucleation 
(ten Wolde & Frenkel, 1997). The initial critical nucleus possesses high free energy, 
thus its formation is only possible by overcoming the energy barrier towards 
nucleation as shown in figure 1.21. The initial critical nucleus is an irreversible, 
transient, thermodynamically stable phase that is capable of independent existence, 
acting as crystal centres for further growth into larger crystals by the diffusion and 
attachment of growth units to its surface and their subsequent incorporation into the 
protein crystal lattice structure. 
 
 
 
 
 
 
 
 
 
 
 Figure 1.21: Hypothetical diagram showing energy barrier for nucleation, taken from (Saridakis & 
Chayen, 2009).  
Nucleation is an entropy driven process. A crystalline state is generally favored by 
lowering the entropy of the system. In order to counterbalance the loss in entropy, a 
decrease in enthalpy must occur to trigger the incorporation of a protein molecule into 
the bulk of a crystal. However, it has been observed that formation of a protein crystal 
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is accompanied by an increase in enthalpy. This suggests that the loss in entropy due to 
crystal formation is balanced by lowering the free energy due to the formation of 
contacts in a protein crystal. Theory, simulations and experiments have predicted that 
density fluctuations near LLPS can significantly reduce the energy barrier to 
nucleation and enhance the rate of crystal nucleation (ten Wolde & Frenkel, 1997, 
Talanquer & Oxtoby, 1998). In addition to the classical nucleation mechanism, a two-
step nucleation mechanism (ten Wolde & Frenkel, 1997, Talanquer & Oxtoby, 1998) 
supported by recent research proposes that protein crystallization proceeds via a two-
step nucleation and growth phase (Erdemir et al., 2009, Vekilov, 2010a, 2005).      
1.3.2.2 Thermodynamics and driving forces for protein crystallization 
The thermodynamics of protein phase transitions are in many ways similar to the 
thermodynamics of phase transitions in colloidal solutions (Hagen & Frenkel, 1994, 
Asherie et al., 1996, Adams et al., 1998, Van Megen & Underwood, 1993). Protein 
molecules in solution prior to the formation of solid condensed phases 
(crystals/amorphous aggregates), are surrounded by water molecules. As the protein 
molecules assemble to form a new phase, the water molecules undergo some 
restructuring or rearrangement. This restructuring is accompanied by changes in the 
Gibbs free energy (Prausnitz & Foose, 2007). The change in Gibbs free energy of 
crystallization,
0
crystG  at constant temperature T is the sum of the contributions from 
the enthalpic term 
0
crystH  and the entropic term 
0
crystS  defined by equation 1.7, 
                                               
000
crystcrystcryst STHG                       1.7 
When protein molecules are engaged in Brownian motion in solution, there is no order 
associated with it. However, when a three-dimensional structuring or order is imposed 
on these protein molecules in the crystal lattice, it is accompanied by a massive 
decrease in entropy that drives crystal formation. This decrease in entropy is associated 
with the loss of six translational and rotational degrees of freedom per protein 
molecule and is only partly compensated for by the newly created vibrational degrees 
of freedom (Finkelstein & Janin, 1989, Tidor & Karplus, 1994). This contributes to an 
increase in free energy,
0
crystG  which disfavours crystallization. This can only be 
compensated for by lowering the enthalpic term, 
0
crystH  or the entropy of 
accompanying processes. However, thermodynamic measurements for several proteins 
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such as lysozyme (Schall et al., 1996) and hemoglobin C (Vekilov, Feeling-Taylor, 
Petsev, et al., 2002), indicate that enthalpic effects are unlikely to favor crystallization 
and that entropic effects are more important. The incorporation of a protein molecule 
into a crystal lattice is associated with the release or additional trapping of structured 
water/solvent molecules (Vekilov, 2012). Hence, the solvent and protein entropy 
changes are integrated into equation 1.7 which is modified into equation 1.8 as shown 
below, 
                                 )(
0000
solventproteincrystcryst SSTHG               1.8 
A more negative 
0
crystG  that aids crystallization is favored by positive sum of
00
solventprotein SS  . The estimated values for 
0
proteinS  from experimental studies are in 
the negative region and the negative contribution is only overcome by positive 
contribution from the 
0
solventS  values (Vekilov & Chernov, 2002). This increase in 
entropy (
0
solventS ) is accompanied by the release of water/solvent molecules upon the 
incorporation of a protein molecule into a crystal lattice. (Vekilov, Feeling-Taylor, 
Yau, et al., 2002).      
1.3.2.3 Methodology for protein crystallization 
Creating the correct conditions for crystallization to occur, often involves screening of 
large numbers of potential solution conditions, which may favour nucleation. Currently 
brute force approaches are employed using high-throughput systems to prepare large 
number of conditions that favour protein crystallization. The general approaches are: 
i. Altering the pH of the buffer in which the protein is dissolved. Changing 
the pH of the protein solution alters the charge on the protein surface.  
ii. Altering the chemical activity of the hydration layer around the protein by 
the addition of salts (e.g. ammonium sulphate).  
iii. Altering the degree of attraction between protein molecules. This is 
achieved by changing the pH or the addition of bridging ions (e.g. ligands). 
iv. Altering the nature of interactions between protein molecules and the 
solvent by the addition of organic solvents (Cohn et al., 1947), long-chain 
polymers (Arakawa & Timasheff, 1985) and non-volatile organic 
compounds (Stauber et al., 2015).  
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v. Altering the temperature and concentration of the protein solution. 
vi. Inducing crystallization in proteins due to the influence of precipitant 
stereochemistry (Stauber et al., 2015, Asherie et al., 2008).   
Chemical precipitants for protein crystallization 
Chemical precipitants are widely used to obtain supersaturation for protein crystal 
growth. The most commonly used precipitants fall into four broad categories: (i) salts, 
(ii) organic solvents, (iii) long-chain polymers, (iv) low molecular weight polymers 
and non-volatile organic compounds.  
The effect of salts on protein crystallization is highly influenced by the ionic species 
that constitute it. Salting-out salts such as CH3COONa, NaCl and Na2SO4 are 
preferentially excluded from the protein surface thereby hydrating the protein molecule 
and the increase in chemical potential associated with the presence of these salts can 
lead to phase separation and formation of the solid phase (Arakawa & Timasheff, 
1982). In contrast, salting-in salts such as KSCN, MgCl2 and CaCl2 extensively bind to 
protein surfaces with their anionic or cationic portion binding to specific protein 
surfaces and the distribution of the counter-ions in the electric double layer around the 
protein, this screening of electric charges on the surface of the protein can lead to 
phase separation and formation of the solid phase (Arakawa & Timasheff, 1982). 
Organic solvents (e.g. ethyl alcohol) induce crystallization in protein solutions by 
reducing dielectric constant of the medium. It is thought that screening effects of the 
solvent promote attraction between protein molecules favoring formation of the solid 
phase (Englard & Seifter, 1990, Cohn et al., 1947). The third class of precipitants 
include long-chain polymers (e.g. polyethylene glycol), which are preferentially 
excluded from the protein surface. (Arakawa & Timasheff, 1985, Ingham, 1990, 
McPherson, 1976). Solid phase formation in the presence of non-volatile organic 
compounds (e.g. 2-methyl-2,4-pentanediol) is also thought to be via preferential 
exclusion from the protein surfaces due to repulsion from their charged residues 
(Bolen, 2004).    
Physical techniques for protein crystallization 
The process of protein crystallization begins from screening for favorable 
crystallization conditions to optimizing crystal growth to obtain diffraction quality 
crystals. Protein crystallization screening trials are usually used to find ‘hits’ or ‘leads’ 
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for the conditions that favor crystallization (Chayen & Saridakis, 2008). Observation 
of crystals, crystalline precipitate and phase separation in solution are leads to 
identifying the suitable conditions that favour the process. Protein phase diagrams have 
also been very effective tools in determining conditions that favour protein 
crystallization (Asherie, 2004). When the conditions are identified, it is followed by 
optimization of the crystallization process. This may be achieved by varying the 
concentration of protein, type and concentration of precipitant/additive, pH or 
temperature.  
Protein crystal screening can take place in the following formats: 
i. Microbatch experiments 
In microbatch experiments, small volumes of protein and precipitant are mixed and 
incubated under low-density paraffin oil (0.87 g.ml
-1
) as shown in figure 1.22. The 
aqueous crystallization drops sink beneath the denser paraffin oil, where they are 
protected from evaporation and contamination (Chayen & Saridakis, 2008). The 
conditions for protein crystallization in a microbatch experimental set-up are constant 
within the time frame of a crystallization experiment and there are no changes in the 
drop volume or pH and the crystals generally do not dissolve (Chayen et al., 1990, 
Chayen, 1998). 
 
 
 
Figure 1.22: Schematic representation of microbatch protein crystallization technique widely used in 
crystallizing proteins. 
ii. Vapour diffusion 
The most commonly used crystallization technique is vapour diffusion as shown in 
figure 1.23, where the protein solution is either a sitting or a hanging drop. This is then 
allowed to equilibrate against a reservoir containing a crystallizing agent at either 
higher or lower concentration than in the drop (Chayen & Saridakis, 2008). Diffusion 
based methods are highly dynamic systems where the conditions change throughout 
the crystallization process. 
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Figure 1.23: Schematic representation of vapour-diffusion protein crystallization technique widely used 
in crystallizing proteins. 
iii. Dialysis 
In this method, the protein solution is initially contained within a semi-permeable 
membrane, which is then allowed to equilibrate against a precipitant solution as shown 
in figure 1.24. Equilibration and diffusion against the precipitant slowly raises the 
supersaturation of the protein solution within the dialysis membrane eventually 
resulting in crystallization (Chayen & Saridakis, 2008).        
 
 
 
 
 
Figure 1.24: Schematic representation of dialysis protein crystallization technique widely used in 
crystallizing proteins. 
iv. Free interface diffusion 
This method involves placing the protein and precipitant solutions in close proximity 
whereby a concentration gradient is established with time and this directs the system 
towards self-nucleation and growth (Chayen & Saridakis, 2008, McPherson, 1999, 
Garcia-Ruiz et al., 2002). 
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v. Microfluidics 
High-throughput crystallization screening is carried out using microfluidic chips 
(Hansen & Quake, 2003). This method not only requires minimum quantities of 
protein and works with maximum pace and efficiency, but also follows fluid flow and 
mass transport principles which may increase the likelihood of protein crystallization 
in solutions (Chayen & Saridakis, 2008, Zheng et al., 2003, Li & Ismagilov, 2010).  
1.3.2.4 Use of molecular engineering and synthetic symmetrisation to promote 
protein crystallization 
Obtaining single well-diffracting single crystals is the major limiting step towards 
protein crystal structure prediction from X-ray crystallographic analysis (DeLucas & 
Bugg, 1987, Chayen et al., 1996). Protein structural data forms the basis of all 
structural genomic studies involving protein structure-function correlations (Darby & 
Creighton, 1993) and also plays a significant role in rational drug design. One of the 
major constraints towards the formation of single crystals is the presence of large 
hydrophilic residues on the surface of the protein that prevents the formation of 
intermolecular contacts required for protein crystallization. Thus, protein surface 
properties play a determining role in the formation of tight intermolecular contacts, 
required for crystal lattice stability. The concept of ‘surface-entropy reduction’ was 
recently proposed to overcome the crystallization barrier by substituting large, bulky 
surface-exposed residues with small amino acids such as alanine that has minimum 
conformational entropy using site-directed mutagenesis (Derewenda, 2004, 
Longenecker et al., 2001, Derewenda & Vekilov, 2006), which was further supported 
by strong theoretical work  (Cieślik & Derewenda, 2009). Among the polar amino 
acids that are surface-exposed, lysine and glutamate are the most prominent (Baud & 
Karlin, 1999), that have evolved a ‘surface-entropy shield’ which prevents their non-
specific aggregation and precipitation (Doye et al., 2004) and their side chains are 
characterized by high conformational energy of ~2 kcal/mol (Avbelj & Fele, 1998). 
Thus, replacing lysine and glutamate residues constitute a good target for surface 
modification and crystal engineering of proteins (Derewenda, 2010).      
Another concept that has been employed to crystallize proteins is by synthetically  
symmetrizing proteins (Banatao et al., 2006). This has been achieved by generating 
symmetric proteins such as homodimers that have increased tendency to crystallize 
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from naturally monomeric proteins by forming disulfide bridges between individual 
cysteine residues introduced by mutagenesis. On similar lines, Yeates and Kent have 
described a concept called ‘racemic protein crystallography’ to solve protein structures 
(Yeates & Kent, 2012). All natural proteins are chiral and the chirality of protein 
molecules has important implications for how they interact with other molecules in the 
cell and how they crystallize. They have utilized the chirality of the crystal space 
groups to generate the mirror image (enantiomer) of a protein molecule, and the mirror 
images that form racemic mixtures had greater potential to crystallize in a wider range 
of possible space groups (Yeates & Kent, 2012). Thus, racemic protein crystallography 
was another novel approach towards obtaining well-ordered crystals for protein 
structure determination (Berg & Goffeney, 1997, Matthews, 2009).     
1.3.3 Understanding protein condensation leading to protein 
aggregation in bio-pharmaceutical industries 
Protein aggregation in bio-pharmaceutical industries is an undesirable form of protein 
self-assembly as it leads to reduced or no biological activity of the potential drug 
molecule and enhanced potential for immunogenicity or side effects. It has emerged as 
one of the most important areas of extensive research and development since the 
primary goal of bio-pharmaceutical industries has been to identify the cause of protein 
aggregation and control protein aggregation at its earliest stage. These protein 
aggregates have primarily influenced the commercialization of drug products by 
reducing their efficacy. Significant amount of research has been carried out to 
understand several aspects of protein self-assembly leading to protein aggregation. The 
broad field of protein aggregation encompasses various aspects such as mechanism 
and driving forces leading to physical aggregation (Chi et al., 2003), aggregation 
mechanisms (Philo & Arakawa, 2009), aggregation kinetics (Morris et al., 2009), 
aggregation predictions (Weiss et al., 2009), theoretical considerations of aggregation 
(Gsponer & Vendruscolo, 2006), inhibition of aggregation (Wang, 2005, Hamada et 
al., 2009) and aggregation related to diseases (Wang et al., 2008). 
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1.3.4 Aqueous two-phase separation systems for industrial 
protein purification  
Polyethylene glycol has been widely used as a crystallizing agent, creating an effective 
attraction between protein molecules due to depletion forces (Gilliland, 1988, 
Anderson & Lekkerkerker, 2002). However, polyethylene glycol has most often been 
used in combination with a salt, resulting in liquid-liquid phase separation of proteins. 
At low salt concentrations, liquid-liquid phase separation of protein occurs due to 
repulsive electrostatic interaction between protein molecules while the nature of the 
salt dictates phase separation at relatively high salt concentrations (Dumetz, Lewus, et 
al., 2008).    
The partitioning of protein between the two phases also depends on the hydrophobicity 
of the protein and the polymer concentration. Protein concentration also influences 
partitioning of protein between the two phases. This method of aqueous two-phase 
separation have found wide applications in the purification of a large number of 
industrial enzymes and separation of virus and virus-like particles (Asenjo & Andrews, 
2011).   
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Chapter 2 
Experimental methods and 
materials 
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2.1 Preparation of materials 
2.1.1 Preparation of buffers 
Analytical grade buffer salts were purchased from Fisher Scientific (Dublin, Ireland) 
and used without further purification. All buffers were prepared in Milli-Q water, 
adjusted to the appropriate pH using either sodium hydroxide (NaOH), hydrochloric 
acid (HCl) or acetic acid (CH3COOH) solutions and filtered through a 0.45 µm nylon 
membrane filter using a Millipore glass assembly filter under vacuum (Merck 
Millipore) before use. Buffers used for SE-HPLC were filtered using the above method 
and degassed using the online degasser. Buffers used for gel electrophoresis were 
degassed using an external vacuum pump.  
2.1.1.1 Preparation of sodium phosphate buffer   
0.1 M sodium phosphate buffer at pH 7.0 was prepared using 15.6 g of sodium 
dihydrogen phosphate dihydrate (Mw of NaH2PO4.2H2O ꞊ 156.007 g.mol
-1
) and 26.8 g 
of sodium phosphate dibasic heptahydrate (Mw of Na2HPO4.7H2O ꞊ 268.07 g.mol
-1
) in 
Milli-Q water and made upto 1 L. The pH was adjusted using a NaOH solution. 0.02% 
(w/v) sodium azide (NaN3) was added to prevent bacterial growth in buffer solutions.  
2.1.1.2 Preparation of sodium acetate buffer 
0.275 M sodium acetate buffer at pH 4.5 was prepared using 16.5 g of glacial acetic 
acid (CH3COOH) and 4.5 g of sodium hydroxide (NaOH) in 1 L milli-Q water. While 
preparing sodium acetate buffers, direct mixing of glacial acetic acid with sodium 
hydroxide was avoided to prevent an explosive exothermic reaction. 
Sodium acetate buffer with salt. 0.275 M sodium acetate buffer at pH 4.8 with 0.325 
M sodium chloride (NaCl) contained 16.5 g of glacial acetic acid (CH3COOH), 6.7 g 
of sodium hydroxide (NaOH) and 76.1 g of sodium chloride (NaCl) in 1L Milli-Q 
water. The pH of sodium acetate buffers were adjusted using CH3COOH or NaOH 
solution as appropriate. 0.02% sodium azide (NaN3) was added to prevent bacterial 
growth in buffer solutions.  
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2.1.1.3 Preparation of Tris-HCl buffers 
1 M Tris-HCl at pH 8.8 and 0.5 M Tris-HCl at pH 6.8 were prepared. 1 M Tris-HCl 
was prepared by dissolving 12.11 g of Tris Base (Mw of Tris Base ꞊ 121.1 g.mol-1) in 
Milli-Q water and made up to 100 ml. 0.5 M Tris-HCl was prepared by dissolving 6.06 
g of Tris Base in Milli-Q water and made up to 100 ml. The pH was adjusted using 
HCl solution.  
2.1.2 Preparation of reagents 
2.1.2.1 Preparation of cell lysis solution 
The cell lysis solution containing 50 mM Tris HCl, 25 mM NaCl and 2 mM EDTA 
(Ethylene diamine tetraacetic acid disodium salt hydrate) in Milli-Q water, adjusted to 
pH 8.0 by the addition of NaOH solution was prepared in a volume of 10 ml, followed 
by the addition of one complete protease inhibitor cocktail tablet (25 MU, Roche) and 
155 mg of DTT (Dithiothreitol).  
2.1.2.2 Preparation of destaining solution for gel electrophoresis 
The destaining solution for gel electrophoresis was prepared by mixing together Milli-
Q water, methanol and acetic acid in the volume ratio of 60/30/10 (v/v/v). 
2.2 Recombinant protein production  
2.2.1 Bacterial cells for DNA transformation reactions 
Two types of bacterial cells were utilized for our experiments involving DNA 
transformation reactions. Library Efficiency
®
 DH5α™ Competent Cells purchased 
from invitrogen (Life Technologies, Dublin, Ireland) were used for the transformation 
of native and mutated DNA material. The transformed cells were grown, harvested and 
subjected to plasmid extraction and purification procedures to obtain recombinant 
DNA. The recombinant DNA was then transformed into BL21-Gold (DE3) Competent 
Cells purchased from Stratagene (U.S.A) for recombinant protein over-expression.    
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2.2.2 Bacterial cell culture  
2.2.2.1 Preparing LB agar plates and LB (Luria-Bertani) broth for bacterial 
growth 
LB agar (Fisher Scientific, Dublin, Ireland) was prepared according to the 
manufacturer’s instructions in Milli-Q water and sterilized by autoclaving at 121°C 
and 0.212 MPa pressure for 20 minutes on a liquid heating cycle in a TOMY SX-500E 
high pressure autoclave. The sterile LB agar was allowed to cool to below 50°C before 
the addition of ampicillin to a final concentration of 100 µg.ml
-1
. The warm LB agar 
was poured into sterile petri dishes under aseptic conditions and left at room 
temperature for a few hours to solidify. The solidified LB agar plates were stored at 
4°C until further use.  
2.2.2.2 Preparation of LB Broth 
LB broth (Fisher Scientific, Dublin, Ireland) was prepared as per the manufacturer’s 
instructions in Milli-Q water and sterilized by autoclaving at 121°C and 0.212 MPa 
pressure for 20 minutes on a liquid heating cycle in a TOMY SX-500E high pressure 
autoclave. Ampicillin was added to the cooled broth to a final concentration of 
100µg.ml
-1
.
  
2.2.2.3 Transformation of Library Efficiency® DH5α™ Competent Cells 
Library Efficiency® DH5α™ Competent Cells purchased from invitrogen (Life 
Technologies, Dublin, Ireland) were transformed using a standard protocol provided 
with the transformation kit. Briefly, the competent cells were thawed, gently mixed 
with the DNA and incubated on ice, followed by a heat-shock procedure. The heat-
shock method involves heat-treatment that triggers the opening of bacterial cell 
membrane pores that then facilitate the entry of DNA material into the cell. The heat-
shocked cells were added to 0.9 ml of S.O.C. medium (Super optimal broth with 
catabolic repressor) purchased from invitrogen (Life Technologies, Dublin, Ireland) at 
room temperature and thoroughly mixed at 37°C  with 225 rpm shaking for 1 hour in 
an Innova 42 incubator shaker (New Brunswick Scientific Co., INC). The 
experimental reactions were diluted 1:5 with S.O.C. medium. 200 µl of the diluted 
mixture was spread on LB agar plates containing 100 µg.ml
-1 
ampicillin. The plates 
were incubated overnight at 37°C for the appearance of white colonies. After 12-18 
hours, a single colony was picked and subsequently grown in 5 ml of LB (Luria-
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Bertani) broth containing 100 µg.ml
-1 
ampicillin to be used for plasmid DNA 
extraction and purification.     
2.2.2.4 Growth and bacterial harvesting for plasmid extraction 
A single colony from a freshly streaked LB agar plate was picked and inoculated in a 5 
ml LB medium containing 100 µg.ml
-1 
ampicillin. The inoculated broth was incubated 
for 8 hours at 37°C with vigorous shaking (300 rpm). The starter culture was diluted 
1/1000 into 100 ml of LB medium and further grown for 12-16 hours at 37°C with 
vigorous shaking (300 rpm). The bacterial cells were harvested by centrifugation at 
6000 g for 15 minutes at 4°C.  
2.2.2.5 Plasmid extraction and purification 
Plasmid DNA extraction was carried out using QIAGEN plasmid purification midi kit 
(Qiagen GmbH, Hilden, Germany) according to a standard manufacturer protocol. The 
supernatant containing the plasmid DNA following plasmid extraction was loaded onto 
the QIAGEN-tip, washed and eluted out. The eluate was subjected to isopropanol 
precipitation; DNA pellets from isopropanol precipitation have a glassy appearance 
and may sometimes be loosely attached to the sides of the tube. Hence, the DNA 
pellets were carefully separated by gently decanting out the supernatant. The glassy 
DNA pellet was washed with 70% ethanol and centrifuged further. The supernatant 
was removed without disturbing the DNA pellet; it was air-dried, redissolved in a 
suitable volume of water and stored at -20°C until further use.           
2.2.2.6 Determination of DNA yield 
The purity of DNA was determined by measuring the absorbance of the diluted DNA 
sample at 260nm and 280nm. The ratio of (Absorbance 260/Absorbance 280) is an 
indication of the nucleic acid purity. A value greater than 1.8 indicates nucleic acid 
content greater than 90%. The concentration of DNA solutions (equation 2.1) were 
estimated by measuring UV absorbance at 260nm, multiplying by the dilution factor, 
and using the relationship that Absorbance260 of 1 ꞊ 50 µg.ml
-1 
of dsDNA.  
          DNA concentration ꞊ Absorbance260 x 50 x (dilution factor) µg.ml
-1
             2.1    
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2.2.2.7 Transformation of BL21-Gold (DE3) competent cells 
BL21-Gold (DE3) competent cells purchased from Stratagene (U.S.A) were 
transformed using a standard protocol; hence a detailed step by step description is not 
required. The competent cells were thawed, gently mixed with the DNA material and 
incubated on ice, followed by a heat-pulse reaction. The heat-shock method involves 
heat-treatment that triggers the opening of bacterial cell membrane pores that then 
facilitate the entry of DNA material into the cell. The heat-pulsed cells were added to 
0.9 ml of S.O.C. medium (Super optimal broth with catabolic repressor) purchased 
from invitrogen (Life Technologies, Dublin, Ireland) at room temperature and then 
incubated at 37°C with shaking at 225 rpm for 1 hour in an Innova 42 incubator shaker 
(New Brunswick Scientific Co., INC). The transformed cells were centrifuged at 200 × 
g for 3 minutes and plated on LB agar plates containing 100 µg.ml
-1 
ampicillin. The 
plates were incubated overnight at 37°C for the appearance of white bacterial colonies.  
2.2.2.8 Preparation of bacterial cell stock 
The transformed E.coli BL21-Gold (DE3) competent bacterial cells with native and 
mutated DNA material were grown on LB agar plates and incubated overnight at 37°C. 
A single colony was picked and subsequently grown in 100 ml of LB broth containing 
100 µg.ml
-1 
ampicillin for 12-16 hours. 2 ml of the inoculated overnight culture was 
pipetted into Nalgene cryogenic vials under aseptic conditions and stored at -80°C in 
an ultra low temperature freezer (New Brunswick Scientific) for further use.  
2.2.2.9 Growing bacterial cultures for recombinant protein production 
The BL21-Gold (DE3) competent cells purchased from Stratagene (U.S.A) and 
transformed with either native or mutated DNA material from frozen stocks were 
streaked using 1 µl clear sterile disposable loops onto sterile LB agar plates. A single 
colony from the streaked plate was picked and allowed to grow in a sterile small 
culture flask containing 100 ml of LB medium and 100 µg.ml
-1 
ampicillin for 12-16 
hours at 37°C in an Innova 42 incubator shaker (New Brunswick Scientific Co., INC) 
with shaking at 225 rpm until the optical density (OD600) was between 0.8 and 1. The 
inoculated small culture medium was divided equally among three large culture flasks 
containing 1.2 L of sterile LB broth with 100 µg.ml
-1 
ampicillin and grown for 4 hours 
at 37°C with shaking at 225 rpm until the optical density (OD600) was 1. 1 ml of 1 M 
IPTG (Isopropyl-β-D-thiogalactopyranoside) purchased from Fisher Scientific 
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(Dublin, Ireland) was added to each flask and the culture was incubated with shaking 
for a further time period of 4-5 hours. Finally, the cell culture was centrifuged at 6000 
rpm for 8 minutes in 250 ml fluorinated Nalgene bottles to pellet the cells. The 
supernatant was discarded and the pellets were stored at -80°C for subsequent protein 
extraction and purification.  
2.2.2.10 Protein extraction from cell lysate 
The bacterial cell pellets were thawed in a water bath at 30°C. To the thawed cell 
pellets, 10 ml of cell lysis solution was added. The bacterial cell pellets were re-
suspended by gentle vortexing to obtain a homogeneous mixture and left to incubate at 
room temperature for 2 hours. 160 µl of 50 mg.ml
-1
 lysozyme was then added to the 
homogeneous cell suspension. The solution was vortexed and incubated for a further 
30 minutes. The cell solution was freeze-thawed 4 × times using liquid nitrogen for the 
freeze and 30°C water bath for the thaw. For the final step 2 ml of 1 mg.ml
-1
 DNase І 
(Bovine Pancreas) and 1 ml of 1 M MgSO4 (Magnesium sulphate heptahydrate) mixed 
just prior to use, was added to the cell lysate. This was incubated at room temperature 
for 30 minutes. The pH of the final cell solution was adjusted to pH 4.5 by the addition 
of glacial acetic acid. The lysate was centrifuged at 10000 rpm for several hours in a 
fiberlite rotor attached to a Thermo Scientific HERAEUS MULTIFUGE 3SR+ 
centrifuge until the cell debris had completely pelleted. The soluble protein solution 
was decanted from the top of the pellet and filtered through 0.22 μm Millex-Gv 
Millipore low protein binding durapore (PVDF) membrane filter units (Millipore, 
Co.Cork, Ireland) before purification by chromatography.  
2.2.3 Site-directed mutagenesis, molecular cloning and DNA 
sequencing 
Recombinant HGD prepared by amplification of the coding sequence from a human 
fetal lens cDNA library were utilized for site-directed mutagenesis and molecular 
cloning experiments. The forward and reverse oligonucleotide primers used to make 
the double mutant proteins were synthesized by Life Technologies (Dublin, Ireland). 
The following forward and reverse primers for the single mutants were obtained: 
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P23V Mutant  
Forward: 5ʹ-GCA GCA GCG ACC ACG TCA ACC TGC AGC CCT AC-3ʹ. 
Reverse: 5ʹ-GTA GG CTG CAG GTT GAC GTG GTC GCT GCT GC-3ʹ. 
P23T Mutant 
Forward: 5ʹ-GCA GCA GCG ACC ACA CCA ACC TGC AGC CC-3ʹ. 
Reverse: 5ʹ-GGG CTG CAG GTT GGT GTG GTC GCT GCT GC-3ʹ. 
R36S Mutant 
Forward: 5ʹ-GCA ACT CGG CGA GCG TGG ACA GCG GC-3ʹ. 
Reverse: 5ʹ-GCC GCT GTC CAC GCT CGC CGA GTT GC-3ʹ. 
R58H Mutant 
Forward: 5ʹ-CCA GTA CTT CCT GCA CCG CGG CGA CTA TGC-3ʹ. 
Reverse: 5ʹ-GCA TAG TCG CCG CGG TGC AGG AAG TAC TGG-3ʹ. 
Site-directed mutagenesis was performed with QuikChange II site-directed 
mutagenesis kit from Stratagene (USA) using oligonucleotide primers for the single 
mutants and HGD wild type plasmid DNA isolated and purified using QIAGEN 
plasmid purification midi kit (Qiagen GmbH, Hilden, Germany). Based on the 
concentration of plasmid DNA and oligonucleotide primers that have been utilized to 
introduce the mutations, table 2.1 illustrates the amounts of different components in 
the PCR mixture.  
Mutants 
of HGD 
P23V R36S R58H P23VR36S P23TR36S P23VR58H 
Reaction 
buffer 
5µl 5µl 5µl 5µl 5µl 5µl 
dS DNA 1.01µl 
(HGD) 
1.01µl 
(HGD) 
1.01µl 
(HGD) 
1.01µl 
(P23V) 
0.94µl 
(R36S) 
1.08µl 
(R58H) 
Oligo #1 0.89µl 1.07µl 0.375µl 1.07µl 0.39µl 0.889µl 
Oligo #2 0.92µl 1µl 0.331µl 1µl 0.37µl 0.919µl 
dNTP 1µl 1µl 1µl 1µl 1µl 1µl 
ddH2O 41.18µl 40.92µl 42.284µl 39.82µl 42.3µl 41.112µl 
Pfu Ultra 1µl 1µl 1µl 1µl 1µl 1µl 
  
Table 2.1:  Composition of PCR mixture for creating double mutants; described in table 2.1 are various 
components (dS DNA: double stranded DNA, Oligo #1, 2: Oligonucleotides 1, 2, dNTP: 
deoxynucleotide mix, Pfu Ultra: Pfu Ultra DNA polymerase) that make up the PCR mixture whose 
individual component composition (volume) is expressed in microlitre (μl).  
Polymerase chain reaction (PCR) generates multiple copies of the DNA material. 
Following polymerase chain reaction (PCR), the mutated DNA material is transformed 
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into Library Efficiency
®
 DH5α™ Competent Cells (invitrogen /Life Technologies, 
Dublin, Ireland) for plasmid DNA extraction and purification. Each of the three double 
mutant plasmids obtained after mutagenesis were sequenced with the T7 promoter 
primer by using an automated capillary DNA sequencer (MRCPPU, College of Life 
Sciences, University of Dundee, Scotland). In order to confirm the desired mutations, 
the plasmid DNA sequences for the double mutants were aligned and compared 
against the wild type plasmid DNA using BLAST (Basic Local Alignment Search 
Tool) available on the NCBI (National Centre for Biotechnology Information, U.S. 
National Library of Medicine) website.  
2.3 Analytical techniques for protein purification and 
protein purity determination 
2.3.1 Size-exclusion chromatography 
2.3.1.1 Working Principle 
Size-exclusion (also known as gel filtration) chromatography is an analytical technique 
which separates proteins and other biological macromolecules based on their 
differences in molecular size (figure 2.1).  
 
 
 
 
 
 
 
Figure 2.1: Separation of a sample mixture based on molecular size by size-exclusion chromatography 
(left). Chromatogram (right) shows the elution profile of molecules depending on their size.   
The stationary solid phase is packed with a porous matrix of spherical particles; the 
mobile phase fills the pores of the matrix and the space between the particles. The 
larger molecules that remain exterior to the pores move quickly through the matrix, 
eluting out at earlier times and the smaller ones that remain trapped in the pore takes 
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longer to elute through the column (Cutler, 2008). This result in selective partitioning 
of the various components of a crude mixture based on their size.     
Those molecules whose actual size is greater than the pore size of the gel used for 
separation, elute out together as the first peak in the chromatogram, and this is referred 
to as the ‘total exclusion volume’ or void volume (V0) which defines the exclusion 
limit for a particular column. Those molecules that can enter the pores of the gel 
matrix diffuse into the internal pore structure and reside within the pores for a certain 
amount of time called the ‘average residence time’ depending on the size of the 
molecules and the pore size distribution of the gel. This volume region on the 
chromatogram over which effective separations can occur is referred to as the 
‘selective permeation’ region. Molecules that are smaller than the pore size of the solid 
matrix are retained for the longest residence time and will elute out of the column as 
the last peak on the chromatogram in the total volume fraction (Vt), which determines 
the ‘total permeation’ limit for a particular column. The largest elution or retention 
volume for any size-exclusion column is the total mobile-phase in the column also 
known as void volume (V0) (Kazakevich & Lobrutto, 2007). The exclusion range 
comprises of those molecules with molecular weights greater than the exclusion limit 
as shown in figure 2.2. 
A given protein can elute between V0 and Vt, designated by the elution volume Ve 
which is related to the partition coefficient Kav as given by equation 2.2. 
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The partition coefficient, Kav shares a log-linear relationship with the hydrodynamic 
radius or radius of gyration of a molecule, which is essentially the effective size of the 
molecule.      
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Figure 2.2: Elution of molecules in size-exclusion chromatography, taken from (Kazakevich & 
Lobrutto, 2007) . 
2.3.1.2 Instrumentation 
Size-exclusion chromatography was performed using an XK50 column connected to 
an external AKTAprime plus system (GE Healthcare BioSciences AB, Sweden) run 
using the PrimeView 5.0 software. The XK50 column was packed with Sephacryl S-
200 HR (GE Healthcare BioSciences AB, Sweden) which is a composite medium 
prepared by covalently cross-linking allyl dextran with N,N'-methylene bisacrylamide 
to form a hydrophilic matrix of high mechanical strength. This packing medium is 
ideal for separating globular proteins in the range between 5 kDa and 250 kDa. The 
column matrix which forms the stationary phase was equilibrated with two bed 
volumes of 0.275 M sodium acetate buffer (pH 4.5) pumped at a flow rate of               
2 ml.min
-1
, controlled by the AKTA prime plus system (GE Healthcare) set to a 
maximum pressure limit of 1 MPa. The proteins were detected by monitoring their 
absorbance profile at 280nm, an extinction coefficient value of 2.09 mg
-1 
ml cm
-1 
was 
used here for protein concentration measurements.  
2.3.1.3 Protein sample preparation and elution 
The clear supernatant containing the crude protein obtained after centrifuging the cell 
lysate was filtered sterilized through 0.22 μm Millex-Gv Millipore low protein binding 
durapore (PVDF) membrane filter units (Millipore, Co.Cork, Ireland) before loading 
on to the column. The sample was loaded by manual run method where the flow rate 
was set to 2 ml.min
-1
 on the AKTA prime plus system.  
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The protein sample fractions were isocratically eluted by running 0.275 M sodium 
acetate buffer (pH 4.5) at a flow rate of 2 ml.min
-1
 using a programmed method (table 
2.2) and collected in long borosilicate glass test tubes on a fraction collector.  
 
 
 
 
 
 
Table 2.2: Programmed method for separation of native HGD and the double mutant proteins from 
crude mixtures by Size-exclusion chromatography.  
2.3.2 Ion exchange chromatography 
2.3.2.1 Working Principle 
Ion-exchange chromatography is a process for separating proteins and biological 
molecules in a sample solution based on their charge characteristics. The charged 
groups on the surface of a protein interact with the oppositely charged groups 
immobilized on the ion-exchange medium (Williams & Frasca, 2001). Negatively 
charged groups bind to positively charged medium and positively charged groups bind 
to negatively charged medium. 
 
 
 
 
 
 
Figure 2.3: Diagram showing the binding affinity of the protein to anion or cation exchangers based on 
net charge of the protein as a function of operating buffer pH, taken from (Williams & Frasca, 2001). 
Breakpoint                             Volume 
(ml) 
Flow 
rate 
ml.min
-1
        
Fraction 
  (ml)        
 
      1         0                   2                 0  
      2                                                                              400                                        2                               0
      3               2300       2       20  
      4      2300       2        0  
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The net charge of a protein depends on the operating buffer pH (figure 2.3). The pH at 
which the net charge of a protein is zero (i.e. the number of positive charges balances 
the number of negative charges) is referred to as iso-electric point (pI). When the 
operating buffer pH is less than the pI of the protein, the protein will have a net 
positive charge and will bind to the cation-exchange medium, whereas when the 
operating buffer pH is greater than the pI of the protein, the protein will have a net 
negative charge and will bind to the anion-exchange medium (figure 2.3). This result 
in selective partitioning of the molecules in a protein mixture based on their surface 
charge differences. Ion-exchange chromatography is performed by adsorption of 
protein to an ion-exchange medium followed by elution using increasing salt gradient 
or using a buffer with a different pH.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Separation of sample mixtures based on their surface charge by cation-exchange 
chromatography.  
2.3.2.2 Instrumentation and technique 
Cation-exchange chromatography was performed using an XK50 column connected to 
an external AKTA prime plus system (GE Healthcare BioSciences AB, Sweden) run 
using the PrimeView 5.0 software. The XK50 column was packed with SP sepharose 
fast flow (GE Healthcare BioSciences AB, Sweden) which is a strong cation 
exchanger composed of crosslinked 6% agarose beads, sulphopropyl (Q) with strong 
cation exchange groups. The column matrix comprises of spherical particles 
substituted with ionic groups that are either negatively or positively charged. The 
highly porous matrix which is packed into the column was then equilibrated with at 
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least five bed volumes of 0.275 M sodium acetate buffer (pH 4.5) pumped at a flow 
rate of 25 ml.min
-1
 controlled by the AKTAprime plus system set to a maximum 
pressure limit of 1 MPa. The equilibration buffer fills the pores of the matrix and the 
space between the spherical particles. The pH and ionic strength of the equilibration 
buffer are selected to ensure binding of the proteins of interest to the medium and 
thorough elution of other impurities. The proteins were detected by monitoring their 
absorbance profile at 280nm. 
2.3.2.3 Protein sample preparation and elution  
The protein fractions from the size-exclusion chromatographic separation were pooled 
and applied to the pre-equilibrated cation-exchange column at a flow rate of 15 
ml.min
-1
. The proteins that bind are concentrated onto the column and the ones that 
possess the same surface charge as of the ionic groups on the column are eluted out 
along with the buffer during sample loading or washing. The wash step was carried out 
by applying five bed volumes of 0.275 M sodium acetate buffer (pH 4.5), at a flow rate 
of 25 ml.min
-1 
to remove unbound protein. When all the unbound protein has passed 
through the column during the wash, a programmed method (table 2.3 for native HGD) 
and (table 2.4 for the double mutant proteins) with a flow rate of 10 ml.min
-1 
and an 
increasing salt gradient of 0 to 0.325 M sodium chloride (NaCl) was set to collect the 
bound proteins eluting out in 0.275 M sodium acetate elution buffer (pH 4.8) and into 
long borosilicate glass test tubes on a fraction collector. The salt ions (Na
+ 
and Cl
-
) 
compete with the bound proteins for the cross-linked resin, the proteins with the lowest 
net charge at a selected pH will elute out first. Proteins with the highest net charge will 
be most strongly bound to the medium and elute out at the end.  
Breakpoint Volume(ml) Salt (%) Flow rate 
(ml.min
-1
) 
Fraction 
(ml) 
    1       0     15      10      0 
    2     1379     15      10      0  
    3     1380     30      10     22 
    4     2904     43      10     22 
    5     3844     85      10      22 
Table 2.3: Programmed method for separation of native HGD from protein mixtures by cation-
exchange chromatography. A linear gradient elution against increasing salt concentration is used to 
elute the proteins of interest. 
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Breakpoint Volume(ml) Salt (%) Flow rate 
(ml.min-1) 
Fraction 
(ml) 
    1       0     15      10      0 
    2      614     15      10      0  
    3      615     30      10     23 
    4     2800     43      10     23 
    5     3844     85      10      23 
Table 2.4: Programmed method for separation of HGD double mutant proteins from protein mixtures 
by cation-exchange chromatography. A linear gradient elution against increasing salt concentration is 
used to elute the proteins of interest. 
After each chromatographic separation, any irreversibly bound material was washed 
off the column with 1 M NaOH in Milli-Q water at a flow rate of 20 ml min
-1 
and the 
medium was regenerated for the next chromatographic separation by washing with at 
least five bed volumes of 0.275 M sodium acetate buffer (pH 4.5).   
2.3.3 Polyacrylamide gel electrophoresis 
2.3.3.1 Working principle 
Electrophoresis is an analytical technique used for qualitative characterisation of 
biological molecules including proteins, peptides, sugars and nucleic acids. The 
charged molecules migrate under the influence of an electric field towards the 
electrode carrying the opposite charge. The mobility of different molecules in a 
mixture depends on their mass allowing them to migrate at different velocities, thus 
separating them into well defined fractions (Westermeier, 2005). The migration 
velocity of a charged molecule, such as protein depends on its pI (iso-electric point) 
and on the pH and ionic strength of the buffer. The pI for a protein is constant and is 
influenced by the composition of amino acids and carbohydrates. The migration of 
protein molecules in an electric field is measured and expressed in terms of its 
electrophoretic mobility (µ), 
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d
                                              2.3 
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where d is the distance travelled from the origin (cm), E is the strength of the electric 
field (V/cm) and t is the duration of electrophoresis (s) (Keren, 2003). 
2.3.3.2 SDS-PAGE 
SDS-PAGE is an electrophoresis method for separating proteins based on their 
molecular weights. SDS is an anionic detergent that binds to the protein at a constant 
weight ratio of 1.4 g SDS/1g protein forming an SDS-protein complex, masking the 
intrinsic charge of the protein and giving it an overall negative charge density. Besides 
SDS, the addition of 2-mercaptoethanol or dithiothreitol (DTT) to the sample buffer 
breaks down the disulphide bridges between cysteine residues on the protein. This type 
of gel is commonly referred to as reducing SDS-PAGE. 
Protocol for SDS-PAGE 
 
Preparation of running gel (12.6%): 
 
             Composition                      Quantity  
            Milli-Q water  
       1M Tris-HCl pH 8.8 
                     3.15 ml 
                     2.5   ml    
          10% (w/v) SDS 
30% Acrylamide/Bis solution 
(37:5:1) 
                     100  µl 
                      
                     4.2   ml 
 
The following components were added to the above mixture after degassing for about 
15 minutes. 
 
10% ammonium persulfate 
(prepared fresh) 
                       
                     50     µl 
                TEMED                      5       µl             
 
Preparation of stacking gel (4%): 
 
                Composition                 Quantity 
                Milli-Q water                  3.05  ml 
         0.5M Tris-HCl pH 6.8 
              10% (w/v) SDS 
30% Acrylamide/Bis solution 
(37:5:1) 
                 1.25  ml 
                 50     µl 
 
                 0.65  ml      
 
The following components were added to the above mixture after degassing for about 
15 minutes. 
 
10% ammonium persulfate 
(prepared fresh) 
                       
                 50     µl 
                TEMED                  5       µl             
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Preparation of sample buffer: 
 
                Composition                  Quantity 
                Milli-Q water 
          0.5M Tris-HCl pH 6.8 
      Glycerol 
4    ml 
                   1       ml 
  0.8    ml  
           10% (w/v) SDS                    1.6    ml 
          Bromophenol blue                    0.5    mg 
 
 
Preparation of protein molecular weight markers:  
 
Combined low range molecular weight protein standards (Bio-Rad, Dublin) with SDS 
reducing sample buffer in the ratio 1:20. The mixture was heated for 5 minutes at 
95°C, cooled and loaded 10 µl/well for full length wells. 
 
Stock sample buffer (stored at room temperature) 
 
                Composition                  Quantity 
                Milli-Q water 
       0.5M Tris-HCl pH 6.8 
                 4.8    ml 
                 1.2    ml 
                  Glycerol 
              10% (w/v) SDS 
                 1.0    ml 
                 2.0    ml 
  0.1% (w/v) Bromophenol blue                  0.5    ml 
 
SDS reducing sample buffer (prepared immediately before use) 
 
             2-mercaptoethanol                   25     µl 
            Stock sample buffer                   475   µl 
 
   
 
 
 
 
 
 
 
Figure 2.5: SDS-PAGE low molecular weight markers run on 12% gel, stained with Coomassie R-250.  
Preparation of protein samples 
Protein samples were combined with the sample buffer in a 1:1 ratio and boiled for 5 
minutes to linearize the proteins. In the case of reducing SDS-PAGE, protein samples 
were combined with pre-mixed sample buffer and 2-mercaptoethanol. Linearized 
protein at a concentration of 0.1 μg .μl-1 was loaded into the wells at 30 µl/well.  
Bovine serum albumin 
Ovalbumin 
Soybean trypsin inhibitor 
Phosphorylase b 
Carbonic anhydrase 
Lysozyme 
66.2 KDa 
97.4 KDa 
45 KDa 
31 KDa 
21.5 KDa 
14.4 KDa 
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Casting the gels 
The gels were run using a mini-protean tetra cell (Bio-Rad, Ireland) assembly. A clean 
pair of spacer and short plates were assembled on a casting stand and secured firmly 
using a casting frame. 10% ammonium persulfate solution and TEMED were added to 
the thoroughly degassed running gel (12.6%) to initiate polymerisation. The combined 
running gel mixture was then dispensed into the space between the clamped plates 
using pasteur pipettes up to 2/3 height. When the gel started to set, tert-amyl alcohol 
(2-methyl-2-butanol) was dispensed on the surface of the gel mixture to prevent 
oxidation of polyacrylamide. The running gel was left to set for about 35-40 minutes. 
When the gel was completely set, the tert-amyl alcohol was washed away with milli-Q 
water and the remaining water on the surface of the gel blotted with a Kimwipe. The 
stacking gel mixture was then poured and allowed to set with the combs inserted to 
form wells. The prepared protein samples and molecular weight markers were loaded 
into the wells by gentle pipetting.      
Running the gels     
The loaded gels were run at 200 V (400 mA) until the band was observed visually at a 
height of 1 cm above the end of the glass plates.  
Staining and de-staining the gels 
The gels were stained in Coomassie Brilliant Blue R-250 staining solution purchased 
from Bio-Rad (Ireland) for 2-5 hours and then destained using the destaining solution. 
The molecular weight of the unknown protein was determined by comparing the 
migration of the protein band against the molecular weight standards.    
2.3.4 High Performance Liquid Chromatography 
2.3.4.1 Working principle/technique 
High performance liquid chromatography (HPLC) is an analytical technique which 
separates various components in a mixture by forcing the mobile phase under high 
pressure through the stationary phase of the column. Size-exclusion-high performance 
liquid chromatography (SE-HPLC) separates molecules based on their molecular size. 
Larger molecules will swiftly pass through the stationary phase of the column eluting 
out first and smaller molecules will take longer to pass through the stationary phase 
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thus eluting out later. Each specific molecule is represented as a peak on the 
chromatogram; the peaks are usually symmetrical and resemble a normal Gaussian 
distribution curve. The distance of the peak maxima from the injection point expressed 
in time units is referred to as the retention time (tR) (Kazakevich & Lobrutto, 2007) 
and this time describes the characteristic behaviour for individual molecules depending 
on their molecular size. Analyte retention volume (VR) is related to the analyte 
retention time (tR) as shown by equation 2.4, provided the HPLC system provides a 
stable mobile phase flow (F).  
                                                          
F
V
t RR                                       2.4 
Retention factor is another chromatographic descriptor which relates retention time (tR) 
to the retention volume (VR) by taking into account the void time (t0) and the void 
volume (V0). The difference between the total retention time (tR) and the void time (t0) 
is called the reduced retention time (tR′), similarly the difference between total 
retention volume (VR) and the void volume (V0) is referred to as reduced retention 
volume (VR′). The ratio of the reduced retention time (tR′) to the void time (t0) or the 
ratio of the reduced retention volume (VR′) to the void volume (V0) is referred to as 
retention factor (k) as shown by equation 2.5 (Kazakevich & Lobrutto, 2007). 
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Thus, retention factor allows valid comparison of the analyte results obtained using 
different column dimensions and mobile phase flow rate. 
2.3.4.2 Instrumentation 
SE-HPLC was performed either using a Superdex 200 10/300 GL or Superdex 75 
10/300 GL SE-HPLC column (GE Healthcare) connected to a Shimadzu SPD HPLC 
system run using Shimadzu LC solution software. The protein samples were 
introduced to the column using the instrument autosampler and detected using a diode 
array detector at 190-800nm. The packing medium for Superdex 200 10/300 GL or 
Superdex 75 10/300 GL SE-HPLC column is a composite mixture of cross-linked 
agarose and dextran. Superdex 200 10/300 GL is ideal for separating proteins in the 
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range between 1000 and 600000 Da and Superdex 75 10/300 GL is ideal for the range 
between 3000 and 70000 Da.  
2.3.4.3 Sample preparation and loading 
SE-HPLC samples for HGD and the double mutant proteins were prepared in 0.1 M 
sodium phosphate (pH 7.0). Prior to loading, 20mM DTT was added to the HGD and 
double mutant proteins to reduce crosslinks formed due to disulfide bridges between 
cysteine residues on the protein surface (Cys-110) (Pande et al., 2000).  
The freshly prepared protein samples with 20mM DTT was forced through either a 
Superdex 200 10/300 GL or a Superdex 75 10/300 GL SE-HPLC column (GE 
Healthcare) and the output which is a size-exclusion chromatogram correlates the 
measured retention time with the molecular weight for the protein. The protein 
samples were initially filter sterilized using 0.22 μm Millex-Gv Millipore low protein 
binding durapore (PVDF) membrane filter units (Millipore, Co.Cork, Ireland). The 
filtered samples were placed in Chromacol borosilicate glass vials (Fisher Scientific, 
Ireland) with a crimp cap and pre-fitted seal and introduced to the column from the 
instrument autosampler. The following specifications were chosen to run a SE-HPLC 
method on Superdex 200 10/300 GL column:  
 
 
 
The specific conditions chosen to run a SE-HPLC method on Superdex 75 10/300 GL 
are detailed as follows: 
 
 
 
  
               Parameters                 Specifications 
             Mobile phase         
                Flow rate 
                Run time 
    Sample injection volume 
    Concentration of sample 
                Pressure                                        
0.1 M sodium phosphate (pH 7.0) 
               0.75 ml.min
-1 
60 minutes  
40 μl 
0.1 mg.ml
-1
-1mg.ml
-1
 
         5-10 bar  
               Parameters                 Specifications 
             Mobile phase         
                Flow rate 
                Run time 
    Sample injection volume 
    Concentration of sample                         
                Pressure                                        
0.1 M sodium phosphate (pH 7.0) 
0.15 ml.min-1 
30 minutes 
40  μl 
    0.2 mg.ml
-1
-1mg.ml
-1
 
   5-10 bar 
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2.3.4.4 Calibration of the column 
Proteins samples for the calibration plot were prepared by dissolving 1mg.ml
-1
 of each 
protein in 0.1M sodium phosphate (pH 7.0), filter sterilized using 0.22 μm Millex-Gv 
Millipore low protein binding durapore (PVDF) membrane filter units (Millipore, 
Co.Cork, Ireland) and loaded on both Superdex 200 10/300 GL (flow rate of 0.75 
ml.min
-1
)
 
and Superdex 75 10/300 GL (flow rate of 0.15 ml.min
-1
)
 
SE-HPLC columns 
(GE Healthcare). All proteins were run separately on both the columns and from the 
retention times obtained for each protein, a characteristic calibration plot was drawn 
for Superdex 200 10/300 GL (figure 2.6) and Superdex 75 10/300 GL (figure 2.7). 
 
 
 
 
 
 
 
Figure 2.6: Calibration plot for Superdex 200 10/300 GL SE-HPLC column using a range of different 
molecular weight proteins.  
 
 
 
 
 
 
 
 
       Figure 2.7: Calibration plot for Superdex 75 10/300 GL SE-HPLC column using a range of 
different molecular weight proteins.  
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2.4 Spectroscopic techniques for protein 
characterization 
2.4.1 Introduction to spectroscopy 
Spectroscopy is a powerful technique that measures and interprets the spectra arising 
from the interaction of matter with electromagnetic radiation. This has led to the 
advent of using spectroscopy for analysing the individual components of complex 
biological molecules such as proteins and nucleic acids. Electromagnetic radiation in 
the form of light is characterised by its energy, E, which is linked to frequency, ν, or 
wavelength, λ, of the radiation through Planck relationship: 
                                        


c
hhE                                                2.6 
where c is the speed of light in vacuum (c = 2.998x10
8 
m/s) and h is the Planck’s 
constant (h = 6.625x10
-34 
J-s).    
 
 
                
 
 
 
 
Figure 2.8: Energy transition due to the absorption of electromagnetic radiation. 
Radiation is an electromagnetic wave with perpendicularly oscillating electric and 
magnetic components. The fundamental process involved in molecular spectroscopy is 
the absorption of a discrete amount of energy in the form of photons to initiate the 
transition of a charged particle from a lower energy state (E1) to a higher energy state 
(E2) (figure 2.8). The excited molecule reverts back to the lower energy state by the 
emission of energy equal to or less than the absorbed radiation referred to as 
fluorescence which will be discussed in section 2.4.1.3. The electrons in the molecule 
are displaced to higher energy levels if the electro-magnetic field intensity is 
sufficiently large and the time taken for the absorption process is about   10
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(Hammes, 2005). An absorption spectrum is obtained when the absorption of light is 
measured as a function of its frequency or wavelength.  
2.4.1.1 UV-Visible absorption spectroscopy: Working principle   
UV-Visible absorption spectroscopy uses the general principle of molecular 
spectroscopy, i.e. when uv-visible light passes through a sample, energy from the 
radiation promotes the electrons from a bonding or non-bonding orbital to an anti-
bonding orbital as illustrated in figure 2.9. UV-Visible spectroscopy uses 
electromagnetic radiation that falls in the wavelength range between 190-380nm 
(ultraviolet region) and 380-780nm (visible region) (Schmid, 2001). The energy gained 
by a molecule due to absorption of radiation also referred to as its potential energy is 
the sum of its electronic, vibrational and rotational energies and can be represented as 
a series of discrete levels or states.  
                      Etotal = Eelectronic + Evibrational + Erotational + Etranslational               2.7 
The differences in energy among the different states follow the order:  
                                    Eelectronic > Evibrational > Erotational                           2.8       
Energy absorbed by a molecule in the UV-Visible region produces changes in the 
electronic energy levels of the molecule. Electromagnetic radiations of longer 
wavelengths in the infrared region of the spectrum are required to bring about 
vibrational and rotational energy changes to the molecules. However in practice, the 
absorption spectrum in the UV-Visible region would consist of a larger electronic 
energy level transition which is usually accompanied by simultaneous smaller changes 
between the vibrational and rotational levels associated with the molecule (Primer, 
1996). 
Electronic transition is an event triggered by the absorption of a photon due to which 
an electron is promoted from an occupied orbital (usually a bonding σ (sigma), π (pi) 
or non-bonding n orbital) of the molecule in its ground state to an unoccupied orbital 
(an antibonding orbital σ* or π*) in an excited state. For most molecules, the lowest 
energy occupied molecular orbitals are σ orbitals, formed either from two s atomic 
orbitals, or from one s and one p atomic orbital, or from two p atomic orbitals having a 
collinear axis of symmetry. The π orbitals, formed from two p atomic orbitals 
overlapping laterally lie at relatively higher energy levels than σ orbitals and the non-
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bonding orbitals that hold unshared electron pairs lie at even higher energy levels. The 
antibonding orbitals (σ* and π*) are orbitals of highest energy (Valeur & Berberan-
Santos, 2012).  
The following electronic transitions are possible as shown in the energy diagram 
below: 
 
  
 
  
 
 
Figure 2.9: Hypothetical energy diagram showing electronic transitions among various orbitals. 
Absorption of photon of appropriate energy can promote one of the π electrons to an 
anti-bonding π* orbital and this type of transition is called π→π* transition, the 
promotion of an anti-bonding electron to an anti-bonding π* orbital results in n→π* 
transition. The σ to σ* transition requires absorption of photon with a wavelength 
which does not fall in the UV-Visible range, thus, only π to π* and n to π* occur in the 
UV-Visible region.    
The energy of electronic transitions is generally in the following order: 
                        n→π* < π→π* < n→σ* < σ→π* < σ→σ*                             2.9 
Electronic transitions arise in proteins due to the presence of the chromophores of the 
aromatic amino acids (phenylalanine, tyrosine and tryptophan), peptide bonds and 
disulphide bonds. Electronic transitions in tyrosine and tryptophan are primarily 
responsible for the absorption spectrum in the region of 280nm. The contribution from 
the aromatic amino acid phenylalanine is more pronounced at 260nm (figure 2.10). A 
strong absorbance profile centred at ~190nm indicates electronic transitions associated 
with the peptide bond. Thus the absorbance maxima in the 190-210nm range is 
attributed to the presence of peptide bonds. The absorption spectra of proteins are not 
only dependant on the aromatic amino acids and peptide bonds but also strongly 
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influenced by their local molecular environments. The structural characteristics of 
proteins that determine the local charge distribution and the local dielectric constant 
also influence the absorption spectrum of proteins. The presence of hydrogen bonding 
and ion-pair interactions also influence the spectrum. This environmental sensitivity of 
protein spectra can be used to obtain detailed information about the amount of α-helix, 
β-sheet and random coil configurations of proteins (Hammes, 2007).  
 
 
 
 
 
 
 
 
 
  Figure 2.10: Absorption spectra of phenylalanine, tyrosine and tryptophan at pH 6.0, taken from 
(Hammes, 2007).  
2.4.1.2 Protein quantification using UV absorption spectroscopy 
Protein concentrations for native HGD and the double mutants were determined 
spectrophotometrically by UV absorbance using the extinction coefficient value of 
2.09 mg
-1 
ml cm
-1 
(Pande et al., 2001). According to Beer-Lambert law,  
                                                   clA                                              2.10 
where A is the absorbance at 280nm, ε is the extinction co-efficient of the protein in 
mg
-1
.ml.cm
-1
, c is the concentration of the protein in mg.ml
-1
 and l is the path length of 
light in cm.  
2.4.1.3 Fluorescence spectroscopy: Working principle 
The term fluorescence refers to the emission of light associated with electrons, which 
in the process of re-arrangement is displaced from an excited state to the ground state. 
Fluorescence is a very useful tool in studying biological processes as it is very 
sensitive to the chemical nature of the molecule and the local environment surrounding 
the molecule. Fluorescence measurements are more complex than absorbance 
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measurements because the molecules are excited at a specific wavelength and 
fluorescence is observed at a higher wavelength. Fluorescence spectral data is 
generally presented as an emission spectrum. A fluorescence emission spectrum is a 
plot of fluorescence intensity vs wavelength. Emission spectra are sensitive to the 
chemical structure of the fluorophore and the solvent conditions. Fluorophores belong 
to two general classes – intrinsic and extrinsic. Intrinsic fluorophores occur naturally, 
whereas extrinsic fluorophores are added to impart spectral properties to a non-
fluorescent molecule. Proteins belong to the class of intrinsic fluorophores; the 
dominant fluorophore in proteins is the indole group of tryptophan. Indole absorbs 
near 280nm and emits near 340nm. The emission spectrum of indole is also highly 
sensitive to solvent polarity. The emission of indole is blue shifted if the group is 
buried within the native protein and its emission may shift to higher wavelengths (red 
shift) when the group is exposed as in an unfolded protein (Lakowicz, 2007).       
2.4.1.4 Protein intrinsic fluorescence measurements by fluorescence spectrometer 
Intrinsic fluorescence measurements of proteins were carried out using Molecular 
Devices SpectraMax M2e (Molecular Devices, USA). Protein samples were placed in 
Hellma Analytics micro fluorescent quartz cells, and excited at 280nm (excitation of 
tyrosine and tryptophan residues) and 295nm (excitation of tryptophan residues only). 
Fluorescence emission spectra were recorded over the wavelength range from 250 to 
450nm with a data interval of 1nm. Buffer samples were used as reference and were 
subtracted from the intrinsic fluorescence measurements of the protein samples. 
2.4.1.5 Circular dichroism spectroscopy: Working principle 
Molecular asymmetry is a general feature of biological macromolecules. Such 
molecules whose mirror images are not identical are referred to as chiral molecules. 
Chiral molecules are distinguished from achiral molecules by their interactions with 
polarized light. Plane polarized light exhibits unidirectional wave propagations. It can 
be decomposed into two circularly polarized components of equal magnitude, one 
rotating in the clock-wise direction (right-handed, R) and the other in the counter-
clockwise direction (left-handed, L) as shown in figure 2.11.  
The two types of measurements that are commonly used to determine the effect of 
molecules on polarized light are optical rotation and circular dichroism (CD). Optical 
rotation is a measure of the rotation of linearly polarized light by a molecule, whereas 
  
 
 
64 
 
circular dichroism is a measure of the differential absorption of the left-handed and 
right-handed circularly polarized light by molecules (Hammes, 2007). When a chiral 
molecule interacts with plane polarized light, the plane is rotated with the amount of 
rotation and direction depending on the molecular asymmetry. If the L and R 
components of the plane polarized light are either unabsorbed or absorbed to equal 
extents, the recombination regenerates the original plane polarized light. However, if 
they are absorbed to different extents, the resulting radiation would possess elliptical 
polarization as shown in figure 2.11 (Kelly et al., 2005).  
 
 
 
 
 
 
 
 
 
Figure 2.11: The left (L) and right (R) circularly polarized components of plane polarized light. When 
the two components have the same amplitude, they combine and generate plane polarized light (left), 
while different magnitudes combine and result in elliptically polarized light (right), taken from (Kelly et 
al., 2005).   
Circular dichroism is an excellent tool for rapid determination of secondary structures 
and folding properties of recombinant proteins. It has been widely used to study 
protein interactions, determine whether a recombinant protein has been folded 
correctly or if mutation has affected its structural conformation (Kelly et al., 2005). 
CD measurements are recorded by spectropolarimeters and are generally reported in 
terms of ellipticity (θ) in degrees which is a measure of the differential absorption of 
the L and R circularly polarized components. CD spectral bands only arise where 
absorption of radiation occurs and they are assigned to explain distinct structural 
features of a molecule. In proteins, the presence of chromophores such as aromatic 
amino acids (absorption in the range from 260 to 320nm), peptide bonds (absorption 
below 240nm) and disulphide bonds (weak absorption centred at 260nm) generally 
give rise to characteristic spectral features. These spectral features contain detailed 
information on the secondary and tertiary structural composition of proteins (Kelly et 
al., 2005, Greenfield, 2006). 
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The peptide bonds in proteins provide information on the secondary structural 
components such as % helix, sheet, and turns. This is principally determined from 
absorption of radiation due to peptide bonds in the region below 240nm. Absorption of 
radiation below 240nm results in a weak but broad n→π* transition centred at 220nm 
and a more intense π→π* transition centred at 190nm. 
Aromatic amino acids may also contribute significantly to the spectral data in this 
region. The different secondary structural components of proteins that give rise to 
characteristic CD spectral data in the far-UV region are illustrated in figure 2.12 (Kelly 
et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: Far-UV CD spectra associated with various secondary structural components. Solid line 
represents α-helix; long dashed, anti-parallel β-sheet; dotted line, type І β-turn; cross dashed line, 31-
helix or poly (Pro) ІІ helix; short dashed line, irregular structure, taken from (Kelly et al., 2005).  
The near-UV CD spectrum that features the tertiary structure of proteins principally 
absorbs in the 260-320nm region due to the aromatic amino acid side chains. Each of 
the amino acids has a characteristic wavelength profile. Phenylalanine shows weaker 
but sharper bands with fine structure between 255 and 270nm, tyrosine shows a peak 
between 275 and 282nm and tryptophan shows a peak close to 290nm with fine 
structure between 290 and 305nm. It has also been observed that the spectral bands 
that arise from tyrosine may overlap with tryptophan (Kelly et al., 2005).  
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The factors that contribute to the shape and magnitude of the near-UV CD spectrum 
are: the number of each type of aromatic amino acid present, their mobility, the nature 
of their environment (H-bonding, polar groups and polarisability) and their spatial 
arrangement in the protein. Although, near-UV CD spectra is not sufficiently advanced 
to yield significant structural insights but it is a reliable way of analysing protein 
structural changes due to amino acid substitutions by site-directed mutagenesis. Thus, 
the near-UV CD spectrum of a protein provides a valuable fingerprint of the tertiary 
structure of a protein, that can be used to compare the native and mutant forms of the 
same protein (Kelly et al., 2005).       
2.4.1.6 Protein sample preparation for CD spectroscopic measurements 
Proteins for CD measurements were prepared at a concentration of 0.2 mg ml
-1 
in 0.01 
M sodium phosphate (pH 7.0) for both far-UV and near-UV CD spectroscopic 
measurements. Far-UV and near-UV CD spectra were recorded on a JASCO J-810 
spectropolarimeter (Institute of Molecular, Cell and Systems Biology, College of 
Medical, Veterinary and Life Sciences, University of Glasgow, Scotland, UK). 0.01 M 
sodium phosphate buffer (pH 7.0) was used as reference. CD spectral data processing 
required baseline correction for the CD spectra of the protein samples. CD spectral 
data for native HGD and the double mutant proteins were drawn and analysed using 
Origin v6.1 software.   
2.5 Protein sample preparation and liquid-liquid 
phase separation (co-existence curve) measurements 
Protein solutions for liquid-liquid phase separation (co-existence curve) measurements 
were prepared by diafiltration against 0.1M sodium phosphate buffer containing 
20mM DTT (Dithiothreitol), pH 7.0 using Ultracel 10 kDa ultrafiltration discs (Merck 
Millipore, Co.Cork, Ireland). Prior to phase separation measurements, protein solutions 
were concentrated by ultrafiltration using Amicon Ultra-4 centrifugal filter units 
(Merck Millipore, Co.Cork, Ireland). Alternatively, to achieve high protein 
concentrations, phase separation of concentrated protein solutions were carried out. 
Protein samples concentrated to 100 mg.ml
-1
 by ultrafiltration were placed in an 
eppendorf tube and subjected to centrifugation at speeds of 1500-2000 rpm for more 
than an hour in a Thermo Scientific HERAEUS MULTIFUGE 3SR+ centrifuge cooled 
to temperatures below the critical temperature for the protein (Tc). This resulted in 
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protein phase separation and the subsequently formed protein-rich phase was collected 
for phase separation measurements.  
The co-existence curve for native HGD was measured using the same method as 
described previously (Broide et al., 1991, Asherie, 2004). Protein sample of known 
concentration was pipetted into a cuvette and placed in Perkin Elmer Lambda 35 
UV/Vis spectrophotometer operated using UV Win Lab-Timedrive Lambda 35 
software. The percent transmission of the sample was recorded at 600nm. The 
temperature of the system was controlled by an external thermostatized water bath unit 
(Thermo Scientific DC10-K10) and monitored using an Omega HH509R 
thermocouple. As the protein solution is cooled, the temperature at which the intensity 
of transmitted light falls to half of its initial value is defined as the clouding 
temperature (Tcloud). Once the transmitted intensity reaches zero the protein solution is 
warmed and the temperature at which the intensity of transmitted light returns to half 
of its initial value is defined as the clearing temperature (Tclear). The phase separation 
(Tph) temperatures are calculated as the average of Tcloud and Tclear. The phase 
separation temperatures (Tph) plotted as a function of protein concentrations defines 
the co-existence curve. Co-existence curves were drawn using Origin v6.1 software.  
2.6 Protein crystal/aggregate formation and solubility 
measurements 
2.6.1 Protein crystal growth 
Protein solutions were initially prepared by diafiltration against 0.1M sodium 
phosphate buffer containing 20mM DTT (Dithiothreitol), pH 7.0 using Ultracel 10 
KDa ultrafiltration discs (Merck Millipore, Co.Cork, Ireland). Protein solutions for 
crystal growth were concentrated by ultrafiltration using Amicon Ultra-4 centrifugal 
filter units (Merck Millipore, Co.Cork, Ireland). Native HGD protein crystals were 
grown in 5mm NMR glass tubes (Hilgenberg GmbH) from protein solutions at  a 
concentration of 50mg.ml
-1
 in the presence of 20μl of 2-methyl-2,4 pentanediol (MPD) 
(Asherie, 2012). Double mutant protein crystals/aggregates were also grown in 5mm 
NMR glass tubes (Hilgenberg GmbH) from protein solutions in 0.1M sodium 
phosphate buffer containing 20mM DTT (Dithiothreitol), pH 7.0 at concentrations less 
than 1mg.ml
-1
 for P23VR36S double mutant incubated at 4°C, concentrations less than 
1mg.ml
-1
 for normal and inverted solubility crystals of P23TR36S double mutant 
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incubated at 4°C and 37°C respectively, and concentrations ≈ 10mg.ml-1  for 
aggregates/crystals of P23VR58H double mutant incubated at 25°C over a time period 
of 12 hours, they were then allowed to settle and gently separated from the 
supernatant. The solid condensed phase i.e. crystals/aggregates separated from the 
proteins monomers were dispersed in fresh buffer and stirred gently at constant 
temperature to ensure uniform mixing.  
2.6.2 Solubility measurements 
The experimental apparatus for solubility measurements consisted of an insulated 
polystyrene box with internal temperature control via a water coil controlled by an 
external thermostatized water bath unit (Thermo Scientific DC30-K20) and monitored 
using a Kane May KM340 differential temperature thermometer with a K type 
thermocouple. Uniform mixing of the sample was regulated by fixing the sealed glass 
vial onto a motor controlled rotor. The solubility lines were measured as described 
previously (Pande et al., 2001, Berland et al., 1992). As the crystals/aggregates melted 
at a fixed temperature, the concentration of the supernatant protein solution in 
equilibrium with the condensed phase is monitored by measuring the absorbance 
(280nm) spectrophotometrically at regular time intervals over a time period of 24-48 
hours. To measure protein concentration in the supernatant, the motor was stopped and 
given sufficient time to allow the protein crystals/aggregates to settle at the bottom of 
the glass vial. The drawn volume of supernatant from the glass vial was replenished 
with fresh buffer and left to equilibrate. After a time period of 24-48 hours, the 
concentration of the supernatant protein solution in equilibrium with the solid 
condensed phase reaches a constant value, this monomer concentration is defined as 
the solubility of the protein for a given temperature. The solubility curves were 
obtained by plotting the protein monomer concentration corresponding to a given 
temperature for a series of temperature values ranging from 0 to 40°C. Solubility 
curves were drawn using Origin v6.1 software.  
2.7 Protein crystal/aggregate formation for imaging  
In order to obtain good quality crystals for phase contrast and polarized light 
microscopy, it was essential to grow protein crystals under controlled solution and 
temperature conditions. Concentrated protein solutions in and around the phase 
boundary for the double mutant proteins were introduced into CoverWell perfusion 
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chambers (Grace Bio-labs) attached to standard microscopic slides, covered and sealed 
with a cover slip. The protein solution within the sealed perfusion chamber is then 
incubated at the specific temperature for crystal/aggregate formation.  
Protein crystals/aggregates formed by the above method were imaged using phase-
contrast and polarization microscopy. An Olympus BX61 microscope with either 60x 
or 100x magnification oil-immersion lens were used to visually observe protein 
crystals/aggregates. The images were recorded using Cell
F 
software and image analysis 
performed using Image
J 
software (James et al., 2015).  
2.8 Protein aggregate formation for kinetic studies 
P23VR58H double mutant proteins prepared in 0.1M sodium phosphate buffer 
containing 20mM DTT (Dithiothreitol), pH 7.0 at concentrations of 5, 7.5 and 10 
mg.ml
-1
 were introduced into CoverWell perfusion chambers (Grace Bio-labs) attached 
to standard microscopic slides, covered and sealed with a cover slip. The monomeric 
protein solution within the sealed perfusion chamber is then incubated at 30°C on a 
DC95 stage controller (Linkam Scientific Instruments, UK) to allow aggregate 
formation to occur. 
The growth of the aggregates was monitored and imaged using phase-contrast and 
polarization microscopy. An Olympus BX61 microscope with either 60x or 100x 
magnification oil-immersion lens were used to visually observe protein 
crystals/aggregates. The images were recorded using Cell
F 
software and the diameter 
of protein aggregates measured using a built-in feature in the Cell
F 
software. The 
P23VR58H double mutant growth curves were drawn and analysed using Origin v6.1 
software. 
2.9 Protein crystallography 
2.9.1 Crystallization 
Protein crystals for X-ray crystallography were grown in 5mm NMR glass tubes 
(Hilgenberg GmbH) from concentrated protein solutions in and around the phase 
boundary (solubility line) for the protein. These solutions were incubated at specific 
temperature conditions for the growth of protein crystals suitable for X-ray 
crystallographic experiments.   
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2.9.2 X-ray data collection 
X-ray data collection was kindly performed by Prof. Amir Khan, Trinity College 
Dublin. X-ray diffraction data for P23TR36S double mutant were collected from both 
rhombic-shaped and rod-shaped crystals that were flash-frozen using glycerol as 
cryoprotectant. Both data sets were collected at PROXIMA 2 beamline at the French 
National Synchrotron Source SOLEIL on an ADSC Q315 area detector. All diffraction 
data were processed, integrated and scaled using iMosflm (Leslie & Powell, 2007) and 
eventually converted to MTZ format using the CCP4i program package (Collaborative, 
1994).  
2.9.3 Molecular replacement and refinement 
The structures of rhombic and rod-shaped crystal types of P23TR36S double mutant 
were solved by molecular replacement using P23T single mutant structure (PDB ID 
4JGF) and R36S single mutant structure (PDB ID 2G98) as search models in Phaser-
MR (McCoy, 2007). After generation of the initial model, iterative cycles of manual 
model rebuilding were carried out using Coot (Emsley & Cowtan, 2004).  
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Chapter 3 
Production, characterisation and 
phase diagrams for HGD and the 
HGD P23VR36S double mutant     
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3.1 Introduction 
3.1.1 Background 
Human γD-crystallin (HGD) is one of the most important structural proteins found in 
the eye-lens. Its phase behaviour is defined by net attractive, short-range, anisotropic 
interactions responsible for liquid-liquid phase separation and protein crystallization 
(Pande et al., 2001, Pande et al., 2000). HGD does not crystallize spontaneously, 
however, there are known single mutants of HGD formed by single amino acid 
substitutions that spontaneously crystallize with significantly lowered solubility when 
compared to the native protein (Pande et al., 2001). One such point mutation is the 
R36S single mutant of HGD which is responsible for the formation of congenital 
cataracts. Arginine at position 36 is not a crystal contact point in the native protein but 
it becomes one in the mutant protein resulting in the crystallization behaviour (Kmoch 
et al., 2000, Basak et al., 2003). The replacement of arginine at position 36 by serine 
results in loss of a polar, charged residue and its replacement by a less polar, 
uncharged residue. Loss of a charged residue makes the protein interactions less 
repulsive, resulting in lowered solubility of the mutant protein (Kmoch et al., 2000, 
Pande et al., 2001). A second type of single amino acid substitution in HGD at position 
23 (P23V, P23T, P23S) inverts the temperature dependence on solubility resulting in 
an unusual phase behaviour (Pande et al., 2005, McManus et al., 2007, Pande et al., 
2009). P23V single mutant is a variant of the naturally occurring P23T single mutant 
which has been found in diverse population groups worldwide (Santhiya et al., 2002, 
Mackay et al., 2004, Nandrot et al., 2003, Shentu et al., 2004, Burdon et al., 2004) and 
is associated with the formation of lamellar (Santhiya et al., 2002), coralliform 
(Mackay et al., 2004), cerulean (Nandrot et al., 2003), fasciculiform (Shentu et al., 
2004), bilateral aculeiform (Vanita & Singh, 2012) and an unclassified silica-like 
nuclear (Burdon et al., 2004) cataract phenotypes. The P23V single mutant does not 
appear naturally in human populations and is formed by replacing proline with valine 
at position 23 on the amino acid chain of native HGD protein. The P23V mutation 
results in the same characteristic phase behaviour as that of the P23T single mutant, 
exhibiting inverted temperature dependence of the solubility line, i.e. the protein forms 
condensed phases (crystals/aggregates) at higher temperatures and melts as the 
temperature is lowered (Pande et al., 2005, McManus et al., 2007). In the native 
protein, position 23 is not a crystal contact point and replacing proline at position 23 
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neither alters the crystal structure of the protein nor does it lead to the formation of 
new crystal contacts in the single mutant protein (Pande et al., 2005, Ji et al., 2013). 
The lowered solubility is attributed to changes in binding energy of the mutant which 
is highly temperature dependent (McManus et al., 2007).  
Figure 3.1: 3D representation of the two amino acid substitutions (P23V and R36S) incorporated in the 
native HGD protein to create the P23VR36S double mutant. 
The first section of this chapter is about the phase diagram for native human γD-
crystallin protein and how well it compares with previously published data and 
secondly, creation of a double mutant protein, incorporating the R36S and P23V single 
mutants (figure 3.1) and exploring the phase behaviour for the newly formed double 
mutant protein.  
3.2 Aim of the study 
Single mutants of HGD have indicated that changes to specific amino acid residues on 
the protein surface contribute to changes in the protein phase behaviour. To increase 
the complexity of the system, we have introduced two single amino acid substitutions 
to the same protein. The first double mutant, P23VR36S, is created by inclusion of 
both the P23V and R36S single mutants of HGD (James et al., 2015). Both single 
mutants are well characterized and demonstrate explicitly different phase behaviours 1. 
Inverted solubility due to the P23V single mutant and 2. Propensity to crystallize due 
to the R36S single mutant. This phase diagram approach was introduced to describe 
the competitive nature of anisotropic interactions in proteins, to qualitatively determine 
if the characteristic behaviour of the individual single mutants were maintained in the 
double mutant and to identify if the position of the phase boundaries of the single 
mutants has been altered when incorporated within the double mutant. Among the 
R36S substitution 
P23V substitution 
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double mutant proteins created to study phase behaviour prediction, P23VR36S was 
first chosen as the phase boundaries for the individual single mutants do not overlap 
when the phase boundaries were re-drawn on the same diagram. The key question is 
which behaviour will be exhibited by the double mutant protein?  
3.3 Results and Discussions 
3.3.1 Production and characterisation of human γD-crystallin 
Human γD-crystallin (HGD) proteins were over-expressed in E.coli as described in 
chapter 2. Chromatographic separation of the crude lysate by size-exclusion 
chromatography (figure 3.2) and cation-exchange chromatography (figure 3.4), 
following extraction indicated that typically 200 mg of purified protein was obtained 
from 7.2 L of bacterial cell culture.  
 
 
 
 
 
 
 
 
Figure 3.2: Size-exclusion chromatogram depicting the primary purification step for native HGD 
protein. 
The protein fractions associated with peak 1 and peak 2 were analysed using SDS-
PAGE. The HGD native protein has a molecular mass of 20,607 ± 1 Da as confirmed 
by intact molecular weight analysis by electrospray ionization mass spectrometry 
performed at the Finger prints proteomics facility, College of life sciences, University 
of Dundee. This molecular mass for HGD is consistent with previously published 
results (Hanson et al., 1998). The presence of a strong band at 21.5 kDa in the lane for 
peak 1 (figure 3.3) confirms that protein extraction has been successful (figure 3.2).  
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Figure 3.3: SDS-PAGE gels confirming elution of native HGD protein into fractions associated with 
peak 1. 
Ion-exchange chromatography of the band identified as HGD completed the 
purification process (figure 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Cation-exchange chromatogram depicting clean elution profile for native HGD protein. 
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Figure 3.5: 12.6% reducing SDS-PAGE gel confirming the purity of native HGD protein. 
The purified protein was characterised by SDS-PAGE (figure 3.5) showing a clean 
monomer band. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: SE-HPLC profile for native HGD, when freshly prepared in 0.1M sodium phosphate buffer 
pH 7.0 in the presence of 20mM DTT. 
Chromatographic analysis of SE-HPLC data confirmed that native HGD protein is 
mostly monomeric (≥ 99% purity), which was confirmed by a reducing SDS-PAGE 
gel (figure 3.5) and shows a major peak at 12.52 min (figure 3.6). From the calibration 
of the Superdex 75 10/300 GL SE-HPLC column, a peak at 12.52 min indicates a 
molecular weight in the region of 20.6 KDa, which is consistent with published results 
(Hanson et al., 1998). 
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3.3.2 Phase diagram for human γD-crystallin: Solubility and 
phase separation measurements 
The coexistence curve (liquid-liquid phase separation) for native human γD-crystallin 
(figure 3.7) was measured. This has been measured previously (Asherie et al., 1998, 
Broide et al., 1991), but to ensure consistency with previous work, this was repeated 
here. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: The phase diagram of human γD-crystallin showing the liquid-liquid coexistence phase 
boundary and liquidus line. To compare the accuracy of our experimentally measured coexistence curve 
(squares) and solubility curve (star-shaped), we redrew previously measured data points for both 
coexistence (circles) (Broide et al., 1991, Asherie et al., 1998) and solubility (upright triangles) (Pande 
et al., 2001) lines. 
The coexistence curve marks the boundary between a homogenous single phase and a 
heterogeneous two phase region at a particular temperature (Asherie et al., 1998, 
Thomson et al., 1987). Figure 3.7 clearly shows that our phase separation 
measurements for native human γ-D crystallin and previously published phase 
separation measurements (Asherie et al., 1998) are in good agreement. The phenomena 
of liquid-liquid phase separation resulting in the formation of protein-rich and protein-
poor phases formed by temperature quenching protein solutions is metastable with 
respect to protein crystallization. However for HGD the formation of crystals does not 
occur spontaneously. Various precipitants such as PEG 8000 (Polyethylene Glycol) at 
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20% (w/v) and (RS)-2-methyl-2,4-pentanediol (MPD) were tested to induce protein 
crystallization. Crystallization was only observed in native HGD solutions in the 
presence of (RS)-2-methyl-2,4-pentanediol (MPD). Protein crystals grew from protein 
solutions at a concentration of 50 mg.ml
-1
 in the presence of 20μl MPD solvent. HGD 
crystals formed were examined by polarization microscopy (figure 3.8).   
 
 
 
 
 
 
 
 
Figure 3.8: Polarization microscopy image showing crystals formed by native HGD protein in the 
presence of (RS)-2-methyl-2,4-pentanediol (MPD).   
 
 
 
 
 
 
 
Figure 3.9: Concentration-time profile for native HGD protein monomers in equilibrium with protein 
crystals at 22°C over a time period of 27 hours. 
Protein crystals thus formed were then used for solubility analysis to determine the 
liquidus line for HGD. The solubility curve (liquidus line) for native human γ-D 
crystallin measured is shown in figure 3.7. Every point on the solubility line is a 
measure of the concentration of protein monomers in solution that has attained 
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equilibrium with protein crystals at a specific temperature, over a time period of 24 - 
48 hours. Figure 3.9 indicates the change in monomer concentration for native HGD as 
it reaches equilibrium at 17°C over 27 hours.  
3.3.3 Production and characterisation of P23VR36S double 
mutant protein 
The P23VR36S double mutant plasmid DNA prepared by site-directed mutagenesis 
was sequenced with the T7 promoter and confirmed to incorporate the two single 
amino acid substitutions, proline (CCC) to valine (GTC) at position 23 and arginine 
(CGC) to serine (AGC) at position 36 within the double mutant (figure 3.10).  
   
Figure 3.10: Plasmid DNA sequence for P23VR36S double mutant of HGD aligned and compared 
against native HGD using BLAST. 
3.3.3.1 Determination of plasmid DNA yield 
The purity and concentration of plasmid DNA obtained following mutagenesis and 
plasmid extraction for native, single and double mutants of HGD are as listed below 
(table 3.1): 
 HGD P23V R36S P23VR36S  
Abs260/Abs280 1.8 1.75 1.8      1.77  
Conc of DNA (ng/µl) 49.3 44.9 52.9      51.4  
                Table 3.1: Purity and concentration of DNA obtained from plasmid purification. 
The P23VR36S double mutant protein was isolated and purified as described in 
chapter 2. Chromatographic separation of the crude lysate by size-exclusion 
chromatography (figure 3.11) and cation-exchange chromatography (figure 3.13), 
following extraction indicated that typically 29 mg of purified protein was obtained 
from 7.2 L of bacterial cell culture.  
 
 
HGD 
P23VR36S 
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Figure 3.11: Size-exclusion chromatogram for P23VR36S double mutant of HGD.    
 
 
 
 
 
 
 
 
Figure 3.12: SDS-PAGE gels confirming elution of P23VR36S double mutant protein into fractions 
constituting peak 1.  
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Figure 3.13: Cation-exchange chromatogram depicting clean elution profile for the P23VR36S double 
mutant. 
The size-exclusion protein fractions associated with peak 1 and peak 2 (figure 3.11) for 
the P23VR36S double mutant were analysed using SDS-PAGE. The P23VR36S 
double mutant protein has a molecular mass of 20,539 ± 1 Da confirmed by intact 
molecular weight analysis by electrospray ionization mass spectrometry. This 
molecular mass for the P23VR36S double mutant is consistent with the expected mass 
value for the specified amino acid substitutions. Peak one corresponded to a molecular 
weight band at less than 21.5 kDa on SDSPAGE (figure 3.12). Cation-exchange 
chromatographic separation completed the purification process (figure 3.13). 
  
 
 
 
 
 
 
 
 
Figure 3.14: 12.6% reducing SDS-PAGE gel showing a single monomer band confirming the purity of 
P23VR36S double mutant protein. 
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Figure 3.15: SE-HPLC profile for P23VR36S double mutant when freshly prepared in 0.1M sodium 
phosphate buffer pH 7.0 in the presence of 20mM DTT.   
Chromatographic analysis using SE-HPLC confirmed that P23VR36S double mutant 
protein is mostly monomeric (≥ 98% purity), also confirmed by reducing SDS-PAGE 
gel (figure 3.14) and shows a major peak at 24 min (figure 3.15). From the calibration 
of the Superdex 200 10/300 GL SE-HPLC column used to isolate the protein, a peak at 
24 min indicates a molecular weight is in the region of 20.5 KDa, which is within the 
range expected for P23VR36S double mutant. 
3.3.3.2 Structural studies of P23VR36S double mutant protein using circular 
dichroism spectroscopy and fluorescence spectroscopy  
Circular dichroism spectra. To examine if structural and conformational changes have 
occurred in the protein due to this double mutation, we have compared the CD spectral 
data of P23VR36S double mutant and native HGD. CD spectra in the far-UV region 
monitors secondary structural or conformational changes in proteins and those in the 
near-UV region monitors tertiary structural changes in proteins. Examination of the 
far-UV and near-UV CD spectra of P23VR36S double mutant shows that it has nearly 
identical secondary and tertiary structures to native HGD. This suggests that the 
P23VR36S double mutation occurs without any significant secondary or tertiary 
structural changes to the native protein. Both P23VR36S double mutant and native 
HGD show a negative ellipticity at around 218 nm on the far-UV CD spectra and also 
display similar spectral features on the near-UV CD spectra for the proteins (figure 
3.16).  
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Figure 3.16: Comparison between secondary and tertiary structures of P23VR36S double mutant and 
native HGD using  far-UV CD spectra (left) and near-UV CD spectra (right). 
There is a slight broadening and blueshift below 220 nm associated with the far-UV 
CD spectra for the P23VR36S double mutant protein (figure 3.16). This blueshift has 
been observed before (Pande et al., 2001). This was explained as the serine (36) 
residue disrupting the normal β-sheet structure resulting in the formation of a ‘β-
buldge’ which is responsible for the observed changes in the far-UV CD spectra 
(Pande et al., 2001). We assume that the same explanation applies to our data. 
Fluorescence spectra. Fluorescence emission spectra of γ-crystallins arise mainly due 
to four tryptophan residues buried within the protein core (Mandal et al., 1985). 
Fluorescence emission spectra for the P23VR36S double mutant and native HGD were 
measured using excitation at 280 nm and 295 nm. The fluorescence emission spectra 
were normalized with respect to protein concentration. The λmax (emission maximum) 
value for P23VR36S double mutant protein was well within the range of those 
observed for all γ-crystallins (λmax from 324 to 335 nm (Kono et al., 1990)) which 
indicates that tryptophan residues in the mutant protein remain buried in the 
hydrophobic core (Mandal et al., 1985). However, a red shift in λmax for tryptophan 
fluorescence is observed in fluorescence spectra of P23VR36S double mutant protein 
(figure 3.17). This red-shift was also observed in the R36S single mutant and is due to 
the greater solvent-exposure of the closest tryptophan (trp-42) residue to the serine 
(ser-36) residue, which resulted in the red shift of the fluorescence emission spectrum 
(Pande et al., 2001).    
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Figure 3.17: Fluorescence emission spectra (excitation wavelength=280 nm (left); excitation 
wavelength=295 nm (right)) for P23VR36S double mutant protein in comparison with native HGD. 
3.3.4 Phase diagram (solubility line) for P23VR36S double 
mutant 
The double mutant protein crystallized spontaneously at low protein concentrations 
(less than 1mg/ml). The liquidus line for the double mutant was measured. The phase 
diagram (figure 3.18) indicates that the liquidus line for the P23VR36S double mutant 
overlaps with that measured for the R36S single mutant (James et al., 2015).  
 
 
 
 
 
 
 
 
 
Figure 3.18: Phase diagram for the single mutants of HGD, P23V and R36S (black lines) and the 
double mutant P23VR36S (blue line) taken from (James et al., 2015). Data for the single mutants of 
HGD are taken from (Pande et al., 2000) and (Pande et al., 2005).  
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The liquidus line for the P23VR36S double mutant indicates that the crystal has 
normal solubility. The inverted temperature dependence of the solubility line 
associated with the P23V mutation is absent (James et al., 2015). It is most likely that 
it is not possible to access the solubility line associated with the P23V mutant as it 
occurs at significantly higher concentrations than it is possible to attain for this double 
mutant, since crystallization occurs at lower protein concentrations and on shorter 
timescales (James et al., 2015).  
3.3.4.1 Controlled crystallization of P23VR36S double mutant 
In order to obtain good quality crystals for phase contrast and polarized light 
microscopy, protein crystals were grown from dilute solutions (less than 1 mg.ml
-1
). 
The double mutant protein formed crystals that are consistent in morphology (figure. 
3.19) and behaviour with crystals of R36S single mutant (James et al., 2015).  
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Phase contrast microscopy images showing crystals formed by R36S single mutant (left) 
and P23VR36S double mutant of HGD (right), taken from (James et al., 2015). 
3.3.4.2 Analysis of P23VR36S double mutant solubility data  
Analysis of the solubility data for P23VR36S double mutant reveals interesting 
information about the phase diagram for the protein. The transfer chemical potentials, 
Δμtrans, for native HGD and a few of its single mutants have been estimated from their 
liquidus/solubility lines as discussed previously (McManus et al., 2007).  
The same method described by (McManus et al., 2007) is employed here to calculate 
the transfer chemical potentials and to examine if the phase boundaries for the double 
mutants can be quantitatively compared against the phase boundaries for the single 
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mutants. This helps us probe if the value of binding energy for the crystals in the 
double mutants are the same as for the single mutants (McManus et al., 2007).  
The transfer chemical potential, Δμtrans, relates to the volume fraction, , using the 
Van’t Hoff law by equation 4.1, 
                               
T
trans




ln                                                      4.1      
Defining X=T0/T and assigning T0= 303K (the temperature at which the solubility lines 
for the P23T and R36S single mutants intersect), the above expression 4.1 for the 
Van’t Hoff law becomes,  
                           X
T
trans







 

0
exp


                                                 4.2   
It is observed that at volume fractions greater than ≈ 0.02, Δµtrans/kT0 does not follow a 
linear relationship with temperature (T). To account for this non-linearity, the second 
virial coefficient, B2, which is defined by (Lomakin et al., 1999) as, 
                               1114 32  eB                                       4.3 
where ε = εeff/kT, and from the LLPS, λ=1.25 and εeff/kTC = 1.27 is included in the 
calculation for the transfer chemical potentials.  
If we employ the linear dependence of Δµtrans/kT0 in the Van’t Hoff law, we find that in 
the low volume fraction region (   < ≈0.02) the solubility line becomes, 
                                    SVexp0                                           4.4 
where                      
 
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0
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 
0
0
T
T
V trans


 ; 
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 
0
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T
TT 
 . 
The transfer chemical potential, Δμtrans for each of the solid phases of the double 
mutant proteins were determined utilizing their solubility data. While plotting 
Δµtrans/kT0 vs. T/T0, we find that proteins with normal solubility have negative slope 
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values and those with inverted solubility have positive slope values. The quantity K 
determines solubility dependence, where
 














 S
T
T
K trans
0
0


.  
Examining the solubility data for the P23VR36S double mutant and the R36S single 
mutant suggests that their liquidus lines almost overlap qualitatively as shown in figure 
3.18. Quantitative estimation of solubility data is allowed by plotting Δµtrans/kT0 vs. 
T/T0 and by determining the value of V for the proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: Temperature dependence on solubility for R36S single mutant and P23VR36S double 
mutant of HGD.  
As illustrated in figure 3.20, the negative slope for Δµtrans/kT0 vs. T/T0, indicates 
normal temperature dependence on solubility for the P23VR36S double mutant. There 
are two competing interactions for the solubility behaviour of the double mutant, 
P23VR36S and it clearly demonstrates that the R36S mutation dominates the 
behaviour (James et al., 2015). The values for the parameters S, the slope for 
Δµtrans/kT0 vs. T/T0 and V, the intercept at T=T0= 303K for the single mutants (P23V, 
R36S) and the double mutant, P23VR36S are detailed in table 3.2. In each case, the 
value of K indicates the solubility nature of the protein. The V values for the single 
mutant, R36S and the double mutant, P23VR36S are almost the same. This clearly 
demonstrates that the behaviour for the P23VR36S double mutant is exclusively 
influenced by the R36S substitution for the double mutant. 
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Table 3.2: Values of the parameters S, slope for Δµtrans/kT0 vs. T/T0 and V, the intercept at T=T0= 303K 
for each protein. 
3.3.4.3 Conclusion 
The phase diagram (co-existence curve and liquidus line) for native human γD-
crystallin was measured and is consistent with previously published results. The first 
double mutant, P23VR36S is a good starting point to validate the concept of protein 
phase diagram prediction based on the phase behaviour of the individual single 
mutants. P23VR36S double mutant created by incorporating the two individual single 
mutants P23V and R36S are soluble following extraction and purification procedures, 
they maintain their native structure upon mutagenesis confirmed by spectroscopic 
techniques and form a solid condensed phase (crystals) in a similar way to one of the 
parent single mutants (James et al., 2015). In addition, the equilibrium solubility line 
for the P23VR36S double mutant overlaps with the solubility line for the R36S single 
mutant. Thus, the morphological and behavioural similarity suggests that the phase 
behaviour due to the second single mutant P23V displaying inverted solubility is 
suppressed in the double mutant. This double mutant provides significant insights into 
the phase behaviour of double mutant proteins that were created by mutagenesis of 
native HGD. However, predicting the phase behaviour of one double mutant from their 
individual single mutants is not sufficiently convincing and hence a second double 
mutant, P23TR36S was created.  
The creation of the first double mutant, P23VR36S also raised a number of questions. 
P23V single mutant has a very unusual phase diagram with inverted solubility, 
however the coexistence curves of the P23V single mutant and native HGD overlapped 
indicating that there is very little difference in the net interaction potential between the 
two proteins (McManus et al., 2007). Therefore, anisotropic/aeolotopic interactions 
accounted for the inverted solubility behaviour which was only engaged in the solid 
phase. Although the amino acid substitution associated with inverted solubility is 
present in the double mutant, the solid phase only displays normal solubility while the 
inverted behaviour due to the P23V substitution is absent (James et al., 2015).  
Protein  S V K = V – S 
HGD -19 4.4 23.4 
P23V 20 5.1 -14.9 
R36S -10 6.9 16.9 
P23VR36S -7.5 6.8 14.3 
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Chapter 4 
Phase diagram and crystal 
structures for the HGD P23TR36S 
double mutant     
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4.1 Introduction 
4.1.1 Background 
The P23T single mutant of HGD is a naturally occurring mutation, formed by 
replacing proline with threonine at position 23 on the amino acid chain of the native 
HGD protein (Pande et al., 2005). It exhibits an inverse temperature dependence of the 
solubility line, i.e. the protein forms condensed phases (crystals/aggregates) at higher 
temperatures that melt as the temperature is lowered (Pande et al., 2005, McManus et 
al., 2007), and this characteristic behaviour is observed at significantly lower 
concentrations than for the native protein.  A number of different structural studies, 
using circular dichroism spectroscopy, NMR and X-ray crystallography have indicated 
that replacement of proline at position 23 with a threonine does not alter the structure 
of the protein (Pande et al., 2009, Pande et al., 2005, Ji et al., 2013). Furthermore, 
there is no indication from these studies that any new crystal contact points are formed 
in crystals of the mutated protein (Pande et al., 2005, Ji et al., 2013). Thus, the lowered 
solubility is attributed to changes in binding energy of the mutant which is highly 
temperature dependent (McManus et al., 2007). The second mutation used here is a 
single amino acid substitution in HGD at position 36 (R36S). As described previously 
in section 3.1.1, this substitution results in spontaneous crystallization of the protein 
and significantly lower solubility than the native protein (Pande et al., 2001).  
Figure 4.1: 3D representation of the two amino acid substitutions (P23T and R36S) incorporated in the 
native HGD protein to create the P23TR36S double mutant. 
This chapter provides a detailed description on the creation of a second double mutant 
P23TR36S (figure 4.1) and exploring the phase diagram for the newly formed double 
R36S substitution 
P23T substitution 
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mutant. This mutant formed two different crystal types and x-ray crystallography has 
been used to investigate the structures of the crystals formed. The results from a 
preliminary analysis of this data are presented. 
4.2 Aim of the study 
The first double mutant created i.e. P23VR36S was shown to exhibit the phase 
behaviour associated with only one of the amino acid substitution i.e. the R36S single 
mutant. The behaviour associated with the other single mutant P23V which 
demonstrated inverse temperature dependence on solubility was not observed.  This 
was not surprising given the low solubility of the double mutant protein. It was not 
possible to concentrate the protein to sufficiently high concentrations to the region of 
the phase diagram, where condensation associated with the P23V single mutant was 
observed. (James et al., 2015). To address this point, a second double mutant i.e. 
P23TR36S which incorporates the two individual single mutants P23T and R36S was 
prepared. While the propensity to crystallize due to the R36S mutation remains, the 
P23T mutation has much lower solubility than P23V (Pande et al., 2005). This allowed 
us to explore if the phase behaviour for the newly created double mutant P23TR36S 
displays both normal and inverted phase behaviours associated with the individual 
single mutants as the liquidus/solubility lines for the individual single mutants (P23T 
and R36S) overlap if they are superimposed. In addition to the analysis of solubility 
data to predict the double mutant behaviour, initial structural analysis for the two 
crystal types formed by the double mutant was performed by Prof. Amir Khan, Trinity 
College Dublin.  
4.3 Results and Discussions 
4.3.1 Production and characterisation of P23TR36S double 
mutant protein 
The P23TR36S double mutant plasmid DNA prepared by site-directed mutagenesis 
using primers for the two individual single mutants (P23T and R36S) was sequenced 
with the T7 promoter. DNA sequencing confirmed the two single amino acid 
substitutions, proline (CCC) to threonine (ACC) at position 23 and arginine (CGC) to 
serine (AGC) at position 36 within the double mutant (figure 4.2).  
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Figure 4.2: Plasmid DNA sequence for P23TR36S double mutant of HGD aligned and compared 
against native HGD using BLAST. 
The P23TR36S recombinant plasmid DNA obtained following mutagenesis was 
analysed for its purity and concentration by measuring the Abs260/Abs280 ratio by UV 
absorbance and equal to 1.86 (a value greater than 1.8 indicates greater than 90% 
nucleic acid content) and 37.6 ng.μl-1 respectively. The protein was expressed and 
purified as described in chapter 2. 
The mutant protein was identified from the various peaks observed in the size 
exclusion chromatogram (figure 4.3) by SDS-PAGE. These fractions were pooled and 
further purified by ion exchange chromatography, producing a well purified product 
(figure 4.4). P23TR36S double mutant protein has a molecular mass of 20,541 ± 1 Da 
as determined by intact molecular weight analysis by electrospray ionization mass 
spectrometry performed at the Finger prints proteomics facility, College of life 
sciences, University of Dundee. This molecular mass for P23TR36S double mutant is 
consistent with the expected mass value for the specified amino acid substitutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Size-exclusion chromatogram depicting the primary purification step for P23TR36S double 
mutant of HGD. 
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Figure 4.4: Cation-exchange chromatogram depicting clean elution profile for P23TR36S double 
mutant. 
 
 
 
 
 
 
 
Figure 4.5: 12.6% reducing SDS-PAGE gel showing a single monomer band confirming the purity of 
P23TR36S double mutant protein. 
Chromatographic analysis using SE-HPLC data confirmed that P23TR36S double 
mutant protein is mostly monomeric (≥ 99% purity), also confirmed by reducing SDS-
PAGE gel (figure 4.5) and shows a major peak at 24 min (figure 4.6). From the 
calibration of the Superdex 200 10/300 GL SE-HPLC column used to isolate the 
protein, a peak at 24 min indicates a molecular weight in the region of 20.5 KDa, 
which is within the range expected for P23TR36S double mutant.  
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Figure 4.6: SE-HPLC profile for P23TR36S double mutant when freshly prepared in 0.1M sodium 
phosphate buffer pH 7.0 in the presence of 20mM DTT.   
4.3.1.1 Structural studies of P23TR36S double mutant protein using circular 
dichroism spectroscopy and fluorescence spectroscopy 
Circular dichroism spectra. Comparison of the CD spectral data for the P23TR36S 
double mutant and native HGD was performed to determine if there were structural or 
conformational changes that occurred in the protein due to this double mutation. CD 
spectra in the far-UV region and near-UV region monitor structural changes in 
proteins. The far-UV and near-UV CD spectral analysis of the P23TR36S double 
mutant shows that it has very similar secondary and tertiary structures to native HGD. 
This suggests that the P23TR36S double mutation occurs without any significant 
secondary or tertiary structural changes to the native protein. Both the P23TR36S 
double mutant and native HGD show a negative ellipticity at around 218 nm on the 
far-UV CD spectra and also display similar spectral features on the near-UV CD 
spectra for the proteins (figure 4.7). Additional broadening and blue-shift below 220 
nm are observed in the far-UV CD spectrum for the P23TR36S double mutant protein 
(figure 4.7). This observation is similar to that observed in the R36S single mutant 
where the serine residue disrupts the normal β-sheet structure resulting in the 
formation of a ‘β-buldge’ which is responsible for the observed changes in the far-UV 
CD spectra for the double mutant protein.  
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Figure 4.7: Comparison between secondary and tertiary structures of P23TR36S double mutant and 
native HGD using  far-UV CD spectra (left) and near-UV CD spectra (right). 
Fluorescence spectra. Fluorescence emission spectra for γ-crystallins arise mainly due 
to four tryptophan residues buried within the protein core (Mandal et al., 1985). These 
tryptophan residues are regarded as excellent reporter groups that monitor structural 
integrity of the protein (Pande et al., 2000). Comparison of the fluorescence emission 
spectra of the P23TR36S double mutant and native HGD at excitation wavelengths of 
280 nm and 295 nm were performed as a confirmation of the CD data. The 
fluorescence emission spectra were normalized with respect to protein concentration. 
The λmax (emission maximum) value for P23TR36S double mutant protein was well 
within the range of those observed for all γ-crystallins (λmax from 324 to 335 nm (Kono 
et al., 1990)) which indicates that tryptophan residues in the mutant protein remain 
buried in the hydrophobic core (Mandal et al., 1985). However, a red shift in λmax for 
tryptophan fluorescence is observed in the fluorescence spectra of P23TR36S double 
mutant protein (figure 4.8). A similar red-shift was also reported for the R36S single 
mutant of HGD due to the greater solvent-exposure of the closest tryptophan (trp-42) 
residue to the serine (ser-36) residue (Pande et al., 2001).  
 
 
 
 
 
 
Figure 4.8: Fluorescence emission spectra (excitation wavelength=280nm (left); excitation 
wavelength=295nm (right)) for P23TR36S double mutant protein in comparison with native HGD. 
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4.3.2 Phase diagram for P23TR36S double mutant 
The double mutant protein crystallizes spontaneously at low concentrations. 
Furthermore, two different crystal types are observed, depending on the temperature at 
which the crystals are grown (figure 4.9). A rhombic shaped crystal is formed at 
temperatures higher than 30°C. These crystals melt as the temperature is lowered 
indicating that the temperature dependence of the solubility line is inverted. At room 
temperature and below, a rod-shaped crystal is formed. As the solution containing 
these crystals is heated, the crystals melt, indicating normal solubility.  The liquidus 
lines for both crystal types were measured (figure 4.10). 
 
 
Figure 4.9: The P23TR36S double mutant forms two different crystal morphologies for the same 
protein; one, a rod-shaped crystal that has normal temperature dependence and a second, with rhombic 
shaped crystals having inverted solubility as shown in figure 4.10 (James et al., 2015).  
There is also a temperature region ≈ 303 K (30°C) on the phase diagram (figure 4.10) 
of the protein where rod-shaped and rhombic-shaped crystal morphologies co-exist 
(figure 4.11) (James et al., 2015).  The P23TR36S crystals share no morphological 
similarities with the P23VR36S crystals. However, the P23TR36S does not form 
aggregates at all. This is interesting given that the P23T single mutant only formed 
protein aggregates at pH 7 (Pande et al., 2005). Although a crystal structure for the 
P23T mutant has been described (Ji et al., 2013), these crystals were formed at pH 4.5. 
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Figure 4.10: Phase diagram showing liquidus lines for the two different crystal morphologies; rod 
shaped crystals with normal solubility and rhombic shaped crystals with inverted solubility, taken from 
(James et al., 2015). Inset shows solubility lines for the single mutants of HGD, P23T and R36S (black 
lines) along with the re-drawn solubility lines for the double mutant P23TR36S (green and orange lines) 
taken from (James et al., 2015). Data for the single mutants of HGD are taken from (Pande et al., 2000) 
and (Pande et al., 2005). 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Phase contrast microscopy image showing the coexistence of the two different crystal 
morphologies for P23TR36S double mutant at ≈ 303 K (30°C), taken from (James et al., 2015). 
4.3.2.1 Analysis of P23TR36S double mutant solubility data 
Solubility data analysis for the P23TR36S double mutant reveals interesting 
information about the phase diagram for the protein. We utilize the method described 
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by (McManus et al., 2007) to analyse the solubility data for the P23TR36S double 
mutant. The transfer chemical potential for the two crystal forms of the P23TR36S 
double mutant protein have been estimated from their liquidus lines as described 
previously (McManus et al., 2007) (refer to section 3.3.4.2). 
Quantitative estimation of the solubility data is allowed by plotting Δµtrans/kT0 vs. T/T0 
and by determining the value of V for the proteins (Table 4.1).  
 
 
 
Table 4.1: Values of the parameters S, slope for Δµtrans/kT0 vs. T/T0 and V, the intercept at T=T0= 303K 
for each protein. 
The liquidus line for the rod-shaped crystals which have normal solubility is shown in 
figure 4.10. There is a small difference in the position of the liquidus line between the 
single and double mutants and the analysis indicates that the change in binding energy 
is ≈ 0.4kT at 303 K. Therefore the P23T mutation is influencing the position of the 
phase boundary for the rod-shaped crystals (which have a liquidus line similar to that 
of R36S) in the double mutant (James et al., 2015). 
 
 
 
 
 
 
 
 
Figure 4.12: Temperature dependence on solubility forP23T, R36S single mutants and the two crystal 
forms of P23TR36S double mutant of HGD, taken from (James et al., 2015). 
Protein S V K = V – S 
HGD -19 4.4 23.4 
P23T 28 7.6 -20.4 
R36S -10 6.9 16.9 
P23TR36S (Normal) -7.3 6.5 13.8 
P23TR36S (Inverted) 24 7.8 -16.2 
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For the rhombic shaped crystals with inverted solubility, a small change in the binding 
energy ≈ 0.2 kT (figure 4.12) is observed when compared to the P23T single mutant. 
The double mutant condenses to form only crystals whereas P23T single mutant have a 
greater tendency to aggregate in solution. The small change in binding energy is 
probably insufficient to explain for the greater tendency of the double mutant to form 
crystals when P23T by itself has a greater tendency to form protein aggregates and 
suggests possible influence from the R36S substitution on crystallization behaviour of 
the double mutant.  
4.3.2.2 Protein crystal polymorphism 
A protein crystal polymorph refers to the occurrence of a protein in more than one 
crystalline form. Protein crystal polymorphism is the most ambiguous phenomenon 
frequently encountered during protein crystallization. It is influenced by a combination 
of various factors such as patchy protein surfaces that contribute to the formation of 
crystal contacts, orientation or symmetry of individual protein molecules in a unit cell 
space lattice, solution and temperature conditions (Pande et al., 2001, James et al., 
2015, Lafont et al., 1997, Fusco et al., 2014). Polymorphic crystals that form under the 
same set of solution parameters (Velev et al., 1998, Ataka & Asai, 1988, Vaney et al., 
2001, Bernardo et al., 2005, Frericks Schmidt et al., 2007, Carter Jr & Carter, 1979) 
tend to form crystal structures with similar free energies of crystallization, therefore 
unravelling the interactions responsible for crystallization and those required to 
maintain a stable polymorphic crystal form is important in understanding the 
occurrence of polymorphism. 
Various physicochemical methods have been employed to identify solution conditions 
favorable for protein crystal growth and as a result many proteins have been shown to 
exhibit crystal polymorphism. Crystal polymorphs of aprotinin (BPTI) were reported 
to be stable under a variety of conditions such as pH, salt and temperature (Veesler et 
al., 2004, Lafont et al., 1997, 1994). One of the polymorphic crystals of BPTI 
displayed inverted temperature dependence of the solubility line (Veesler et al., 2004). 
Proteins such as L-asparaginase have produced polymorphs that have similar space 
groups but different crystal lattice contacts, due to Ca
2+
 specific binding (Michalska et 
al., 2008).  
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For the double mutant, P23TR36S, only a temperature change is required to transition 
between the two crystal polymorphs formed. Polymorphic crystal behaviour has also 
been previously reported in BPTI (Veesler et al., 2004), the only factor controlling the 
transition between the two crystal polymorphs is temperature. To examine this crystal 
polymorphism and to analyse what factors contribute to the shifts in phase boundaries 
for the two crystal types of the P23TR36S double mutant in comparison to the 
individual single mutants, X-ray crystallographic analysis of the polymorphic crystals 
were performed.  
4.3.3 Protein crystallography for the P23TR36S double 
mutant crystals 
High-resolution atomic structures for native-HGD and its single mutant proteins such 
as P23T, R36S and R58H are published and available in the protein data bank (PDB). 
Here we describe for the first time, the structures of the two crystal types formed by 
the P23TR36S double mutant of human γD-crystallin protein measured using X-ray 
crystallography. Both P23TR36S double mutant protein crystals provided fully 
measurable sets of x-ray reflections which gave rise to complete diffraction patterns 
for the two crystal forms as shown in figure 4.13 and figure 4.14.  
 
 
 
 
 
 
 
 
 
Figure 4.13: X-ray diffraction pattern obtained for the rhombic crystal of the P23TR36S double mutant 
having inverted solubility. 
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Figure 4.14: X-ray diffraction pattern obtained for the rod-shaped crystal of the P23TR36S double 
mutant having normal solubility.   
4.3.3.1 Preliminary analysis 
The rhombic-shaped crystal of P23TR36S double mutant with inverted solubility 
diffracted to a resolution of 1.24 Å and initial indexing of the diffraction pattern 
indicated that the rhombic crystal belonged to the P21 space group with monoclinic 
symmetry and unit cell dimensions of a ꞊ 44.02 Å, b ꞊ 31.7 Å, and c ꞊ 52.5 Å (α ꞊ γ ꞊ 
90.00° and β ꞊ 91.29°). The rod-shaped crystal of P23TR36S double mutant with 
normal solubility diffracted to a resolution of 2.2 Å. Initial indexing of the diffraction 
patterns indicated that the rod-shaped crystal belonged to the P212121 space group with 
orthorhombic symmetry and unit cell dimensions of a ꞊ 54.04 Å, b ꞊ 82.1 Å, and c ꞊ 
106.25 Å. For the rhombic crystals with inverted solubility the space group consists of 
one protein molecule per asymmetric unit with an estimated solvent content of ~31% 
(Vm ꞊ 1.78 Å
3/Da) as evaluated by Matthew’s coefficient (Matthews, 1968), while for 
rod-shaped crystals with normal solubility the space group comprises of two protein 
molecules per asymmetric unit with an estimated solvent content of ~57% (Vm ꞊ 2.86 
Å
3
/Da). Details of the data collected for both crystal types are shown in table 4.2. 
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Table 4.2: Data collection for rhombic and rod-shaped crystals of P23TR36S double mutant.  
The corresponding data for the crystals of the single mutants (P23T, R36S) (table 4.3) 
is provided for comparison with the double mutant crystal types. 
 
 
 
 
Table 4.3: Data collection for P23T and R36S single mutant crystals of HGD.  
The mosaicity value for protein crystals is another important diffraction characteristic 
parameter to determine crystal quality. The measurement of the rocking width of the 
crystal’s reflections quantifies the crystal mosaicity (Wiencek, 1999). Most single 
protein crystals comprise a regular arrangement of the unit cells interrupted by lattice 
defects. The diffraction pattern for a single protein crystal can be obtained by adding 
the resulting diffraction patterns arising from mosaic blocks with slightly different 
orientations. Mosaicity values between 0.2° and 0.5° are considered ideal for good 
quality protein crystals as it reflects upon the success of the X-ray diffraction 
experimental procedure (Drenth, 2007). Both the crystal forms read low mosaicity 
values of 0.35° for the rhombic-shaped crystals (inverted solubility) and 0.5° for the 
rod-shaped crystals (normal solubility). Although a full refinement of the x-ray data 
has not yet been performed, some initial observations have been made. A molecular 
replacement with the existing crystal structures for the single mutant proteins (from the 
PDB) has been performed using COOT. Superposition of the double mutant structures 
Data Collection Rhombic crystal Rod-shaped crystal 
Resolution range 44.01 - 1.2Å 48.16 - 2.2Å 
Number of  observations 
Measured 
Unique 
Rmerge (within I+/I-) 
< I / σI > 
Completeness (%) 
Multiplicity 
 
157974 
41264 
0.096 
8.1 
99.6 
3.8 
 
164792 
24765 
0.121 
9.2 
99.9 
6.7 
Data Collection P23T crystal R36S crystal 
Resolution range 30.1 - 2.5Å 29.68 - 2.2Å 
Space group 
Completeness (%) 
Cell dimensions 
P 1 21 1 
100.0 
a ꞊ 37.55 Å 
b ꞊ 101.93 Å 
c ꞊ 41.37 Å 
α꞊γ꞊ 90°,β꞊ 96.54° 
P 21 21 21 
91.2 
a ꞊ 54.38 Å 
b ꞊ 81.78 Å 
c ꞊ 106.28 Å 
α꞊β꞊γ꞊ 90° 
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with their single mutant counterparts has been performed using Chimera v1.10.2 and is 
illustrated in figures 4.15 and 4.16. 
 
 
 
 
 
 
 
 
 
Figure 4.15: Superposition of the structures for the P23TR36S rhombic crystal (inverted solubility) and 
the P23T structure from the PDB (green, PDB ID: 4JGF). 
 
 
 
 
 
 
 
 
 
Figure 4.16: Superposition of the structures for the P23TR36S rod-shaped crystal (normal solubility) 
and the R36S structures (green, PDB ID: 2G98). 
Full refinement of the crystal structures for the two crystal forms of P23TR36S double 
mutant are not performed here, however, initial data analysis performed by Prof. Amir 
Khan, Trinity College Dublin suggests small differences in the local structures 
between the single mutants and the two crystals formed by the P23TR36S double 
mutant. A symmetry map showing the closest symmetry molecules for the P23TR36S 
double mutant protein within a 50 Å radius is shown in figure 4.17.  
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Figure 4.17: Symmetry map showing the symmetry related molecules for the P23TR36S double mutant 
protein (normal solubility crystal type) within a 50 Å radius. 
4.3.3.1 Structural changes associated with the Pro to Thr substitution at site 23 
for the rhombic-shaped P23TR36S double mutant crystals (inverted solubility)     
The initial electron density map for the P23TR36S double mutant rhombic crystal 
shows well-defined electron density for the threonine residue that replaces the proline 
residue in the double mutant (figure 4.18). Although the equilibrium solubility line for 
the rhombic-shaped P23TR36S double mutant crystal with inverted solubility was 
shown to be qualitatively consistent with the P23T single mutant which lacks 
molecular contacts, the initial electron density map for the rhombic-shaped P23TR36S 
double mutant crystals with inverted solubility suggest the formation of a new 
molecular contact which is apparently absent in the P23T single mutant: the Oγ1 group 
of the Thr23 (due to mutation at site 23) side chain in the double mutant interacts with 
the NH group of the Gly129 backbone possibly via hydrogen bond formation at atomic 
distances of 3.28 Å. The only known crystal structure for the HGD P23V single mutant 
was obtained for crystals grown at pH 4.6 (Ji et al., 2013). In that crystal structure, no 
new contact at position 23 was observed. However, the structure in that work was 
obtained from crystals in which the asymmetric unit was a dimer. For this new crystal 
structure, the crystals were formed at physiological pH and the asymmetric unit is a 
monomer. If the formation of a molecular contact around site 23 is confirmed after a 
full refinement, this could explain why the P23TR36S double mutant (rhombic-shaped 
with inverted solubility) only forms crystals when the P23T single mutant by itself has 
a greater tendency to aggregate in solution.  
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The structure of P23T single mutant in the PDB indicated local conformational 
changes such as Nε2 group of the imidazole ring of His22 forming a hydrogen bond 
with Tyr16 side chain and Nδ1 group of the imidazole ring of His22 interacting with 
the backbone carbonyl group of Ser20 through a hydrogen bond (Ji et al., 2013). The 
above mentioned local conformational changes were almost absent in the P23TR36S 
double mutant rhombic crystal with inverted solubility. However, the minor structural 
readjustments which were part of the P23T single mutant around the Trp42 side chain 
were retained in the double mutant with no major changes in the molecular contact 
distances. Thus, it can be inferred that the formation of the new intermolecular contact 
around Thr23 in the double mutant has most likely contributed to a more tight crystal 
packing in the rhombic crystal with reduced solvent content of ~31%. This low solvent 
content in the double mutant crystal is noteworthy. 
 
Figure 4.18: Electron density map showing the intermolecular lattice contacts formed in the rhombic 
shaped P23TR36S double mutant with respect to the mutation at site 23.  
4.3.3.2 Structural changes associated with the Arg to Ser substitution at site 36 for 
the rhombic-shaped P23TR36S double mutant crystals (inverted solubility)   
The initial electron density map around site 36 for the P23TR36S double mutant 
rhombic crystal suggests that electron density is poor around the region of mutation 
where the serine residue replaces the arginine residue in the double mutant (figure 
4.19). However, the same mutation when present in the single mutant has a very well-
defined electron density map. Also, unlike the single mutant for which substituting 
arginine by serine at site 36 results in the formation of a crystal contact, the same 
mutation in the P23TR36S double mutant for the rhombic crystals occur with the loss 
  
 
 
106 
 
of this specific crystal contact. The electron density map of R36S single mutant 
suggests that Oγ group of the Ser36 side chain of molecule B interacts with the Nδ2 
group of the Asn24 side chain of molecule B at distances of 2.78 Å (Kmoch et al., 
2000). However, this interaction at short molecular distances is not present in the 
P23TR36S double mutant rhombic crystal with a mutation at site 36.  For the rhombic 
crystal at site 36, there is likely no molecular contact as the Oγ group of the Ser36 side 
chain is at a long distance from the nearest NH1 group of the Arg140 side chain (figure 
4.19). 
 
Figure 4.19: Electron density map showing the lattice contacts formed in the rhombic shaped 
P23TR36S double mutant with respect to the mutation at site 36.  
4.3.3.3 Structural changes associated with the Arg to Ser substitution at site 36 for 
the rod-shaped P23TR36S double mutant crystals (normal solubility) 
The initial electron density map for the P23TR36S double mutant rod-shaped crystal 
shows well-defined electron density for the serine residue that replaces the arginine 
residue in the double mutant (figure 4.20). The equilibrium solubility line for the rod-
shaped P23TR36S double mutant crystal with normal solubility was shown to be 
qualitatively consistent with the R36S single mutant. The R36S single mutant forms a 
crystal contact around site 36 (the Oγ group of the Ser36 side chain of molecule B 
interacts with the Nδ2 group of the Asn24 side chain of molecule A at distances of 
2.78 Å) in the single mutant (Kmoch et al., 2000). In the double mutant P23TR36S 
which forms the rod-shaped crystal, the presence of the same crystal contact as that of 
the R36S single mutant around site 36 is observed except at slightly shorter molecular 
distances (the Oγ group of the Ser36 side chain of molecule B interacts with the Nδ2 
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group of the Asn24 side chain of molecule B at distances of 2.57 Å (figure 4.20)). The 
slightly shorter molecular distance suggest that the crystal packing around site 36 
remains intact in the double mutant and a comparatively tighter packing with no major 
differences between the structures for the rod-shaped crystal and the R36S single 
mutant crystal. This confirms that the R36S substitution is the driving force for the 
formation of the rod-shaped crystals for the P23TR36S double mutant.  
Figure 4.20: Electron density map showing the lattice contacts formed in the rod-shaped P23TR36S 
double mutant with respect to the mutation at site 36 on molecule B.  
4.3.4 Conclusion 
Creation of the first double mutant, P23VR36S, was the initial step towards protein 
phase diagram prediction from phase behaviours of the individual single mutants. 
However, it was understood that P23VR36S double mutant by itself was not sufficient 
enough to validate the concept of protein phase diagram prediction. Hence, the second 
double mutant, P23TR36S was created for further investigative analysis of the 
concept. P23TR36S double mutant proteins are soluble following extraction and 
purification procedures, they retain their native structure upon mutagenesis confirmed 
by spectroscopic techniques and most significant of all, they formed crystals with two 
different morphologies for the same protein; one, a rod-shaped crystal that has normal 
temperature dependence on solubility and a second, with rhombic shaped crystals 
having inverted solubility (James et al., 2015).  
X-ray crystallographic analysis of the two crystal morphologies reveals interesting 
observations about the P23TR36S double mutant. The formation of the new molecular 
contact around site 23 for the rhombic crystals of P23TR36S double mutant could 
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possibly explain for the formation of crystals when mutation around the same region in 
the single mutant has a greater tendency to form protein aggregates. Secondly, the 
formation of the P23TR36S rod-shaped crystal with normal solubility whose behaviour 
is purely driven by the R36S substitution can be inferred from the initial structural 
analysis of the mutation around site 36 for the double mutant. Thus, crystallographic 
evidence provides supporting evidence in addition to the phase boundaries for the 
dramatic phase transitions pertaining to the P23TR36S double mutant. A table 
summarizing the structural changes associated with the single and double mutants is 
provided below (table 4.4).       
 
P23T crystal R36S crystal Double mutant 
(rhombic-shaped) 
Double mutant 
(rod-shaped) 
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Crystal contact 
absent in the 
single mutant. 
 
Crystal contact 
absent in the 
single mutant. 
 
Molecular contact 
formed in the 
double mutant. 
 
Molecular contact 
absent in the 
double mutant. 
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e 
3
6
 
 
Crystal contact 
absent in the 
single mutant. 
 
Crystal contact 
formed in the 
single mutant. 
 
Molecular contact 
absent in the 
double mutant. 
 
Molecular contact 
formed in the 
double mutant. 
 
Table 4.4: Table summarizing the structural changes associated with the single and double mutants of 
HGD due to mutations at site 23 and 36. 
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Chapter 5 
 Phase diagram and aggregate 
growth rate for the HGD 
P23VR58H double mutant 
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5.1 Introduction 
5.1.1 Background 
The third double mutant type, P23VR58H, was created by incorporating the P23V 
amino acid substitution associated with inverted solubility and the R58H substitution 
associated with crystallization and normal solubility. This double mutant is formed by 
replacing proline with valine at position 23 on the amino acid chain of native HGD 
protein exhibiting inverted temperature dependence on solubility i.e. the protein forms 
condensed phases (crystals/aggregates) at higher temperatures and melts as the 
temperature is lowered (Pande et al., 2005, McManus et al., 2007). The other single 
amino acid substitution in HGD (R58H) is formed by replacing arginine with histidine 
at position 58 on the amino acid chain of native HGD. The R58H single mutant, 
similar to the R36S single mutant crystallizes with an almost identical liquidus line 
(Pande et al., 2001). However, the difference in their crystallization kinetics (slow 
crystallization) makes the R58H single mutant 100 times more soluble than the R36S 
single mutant (Pande et al., 2001). The R58H single mutant is responsible for the 
formation of aculeiform cataract (Basak et al., 2003, Pande et al., 2001).  
The R58H single mutant is a crystal contact point for the native protein but the 
strength of the intermolecular ion-pair interaction at this position decreases upon 
mutagenesis (Basak et al., 2003). In the native protein, aspartate at position 156 for 
native HGD forms strong intermolecular ion-pair interaction with the arginine at 
position 58, mediated by direct hydrogen bonds (Basak et al., 2003). However, 
substituting arginine with histidine in the single mutant, results in lessening the 
strength of the strong, protein-protein intermolecular interaction at the mutation site 
(Basak et al., 2003). The solubility of the mutant protein is lower than that of the 
native version and the protein crystallizes, and the liquidus line for the R58H mutant is 
very similar to that of the R36S variant. However, the kinetics of crystallization is very 
different. The R58H mutant crystallizes far more slowly than the R36S and it can be 
concentrated to over 100mg/ml before crystallization occurs. This chapter provides a 
detailed description on the creation of a third double mutant P23VR58H (figure 5.1) 
and exploring the phase diagram for the newly formed double mutant. 
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Figure 5.1: 3D representation of the two amino acid substitutions (P23V and R58H) incorporated in the 
native HGD protein to create the P23VR58H double mutant. 
5.2 Aim of the study 
The creation of the third double mutant, P23VR58H incorporating the P23V and the 
R58H single mutants allowed us to access the higher concentration region of the phase 
diagram where the inverted solubility due to the P23V single mutant is observed which 
was inaccessible for the first double mutant P23VR36S (in chapter 3). 
5.3 Results and Discussions  
5.3.1 Production and characterisation of P23VR58H 
double mutant protein 
The P23VR58H double mutant recombinant DNA was sequenced with the T7 
promoter and confirmed to include the two single amino acid substitutions, proline 
(CCC) to valine (GTC) at position 23 and arginine (CGC) to histidine (CAC) at 
position 58 within the double mutant.  
 
Figure 5.2: Plasmid DNA sequence for P23VR58H double mutant of HGD aligned and compared 
against native HGD using BLAST. 
The purity and DNA concentration for the P23VR58H double mutant was measured to 
be 1.84 (A260nm/A280nm) and 80.8 ng.μl
-1
, respectively.  
   HGD 
P23VR58H 
R58H substitution 
P23V substitution 
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Following size exclusion chromatography (figure 5.3), SDS-PAGE identified the 
mutant protein peak (figure 5.4). These fractions were pooled and further purified by 
ion exchange chromatography, producing a well purified product (figure 5.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Size-exclusion chromatogram depicting the primary purification step for P23VR58H double 
mutant of HGD. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: 12.6% reducing SDS-PAGE gel showing a single monomer band confirming the purity of 
P23VR58H double mutant protein. 
 
 
 
 
 
 
 
 
 
Peak 2 
Peak 1 
0 500 1000 1500 2000 2500
0
200
400
600
800
1000
1200
8.0
8.2
8.4
8.6
8.8
9.0
9.2
U
V
 a
b
s
o
rb
a
n
c
e
 (
m
A
u
)
Volume (ml)
 UV absorbance
 Conductivity
  
 C
o
n
d
u
c
ti
v
it
y
 (
m
S
/c
m
)
  
 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Cation-exchange chromatogram depicting clean elution profile for P23VR58H double 
mutant.  
The P23VR58H double mutant protein has a molecular mass of 20,589 ± 1 Da, 
determined by intact molecular weight analysis by electrospray ionization mass 
spectrometry. This molecular mass for P23TR36S double mutant is consistent with the 
expected mass value for the specified amino acid substitutions. Chromatographic 
analysis by SE-HPLC data confirmed that the P23VR58H double mutant protein is 
mostly monomeric (≥ 99% purity) and shows a major peak at 12.53 min (figure 5.6). 
From the calibration of the Superdex 75 10/300 GL SE-HPLC column used to isolate 
the protein, a peak at 12.53 min indicates a protein molecular weight in the region of 
20.5 KDa, which is within the range expected for P23VR58H. 
 
 
 
 
 
 
 
Figure 5.6: SE-HPLC profile for the P23VR58H double mutant when freshly prepared in 0.1M sodium 
phosphate buffer pH 7.0 in the presence of 20mM DTT.   
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5.3.1.1 Structural studies of P23VR58H double mutant protein using circular 
dichroism spectroscopy and fluorescence spectroscopy 
Circular dichroism spectra. The CD spectral data of P23VR58H double mutant and 
native HGD were compared to examine if structural and conformational changes 
occurred upon mutagenesis. The far-UV and near-UV CD spectral analysis of the 
P23VR58H double mutant indicates that it has very similar secondary and tertiary 
structures to native HGD. Both the P23VR58H double mutant and the native HGD 
show a negative ellipticity at around 218 nm on the far-UV CD spectra and also 
display similar spectral features on the near-UV CD spectra for the proteins (figure 
5.7). 
 
  
 
 
 
Figure 5.7: Comparison between secondary and tertiary structures of P23VR58H double mutant and 
native HGD using  far-UV CD spectra (left) and near-UV CD spectra (right). 
Fluorescence spectra. The fluorescence emission spectra of the P23VR58H double 
mutant and native HGD at excitation wavelengths of 280 nm and 295 nm were 
compared to confirm if protein structural change occurs upon mutagenesis. The 
fluorescence emission spectra were normalized with respect to protein concentration. 
The λmax (emission maximum) value for P23VR58H double mutant protein (figure 5.8) 
was well within the range of those observed for all γ-crystallins (λmax from 324 to 335 
nm (Kono et al., 1990)) which indicated that tryptophan residues in the mutant protein 
remain buried in the hydrophobic core (Mandal et al., 1985).  
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Figure 5.8: Fluorescence emission spectra (excitation wavelength=280nm (left); excitation 
wavelength=295nm (right)) for P23VR58H double mutant protein in comparison with native HGD. 
5.3.2 Phase diagram (solubility line) for P23VR58H double 
mutant 
The P23VR58H double mutant principally forms large amorphous protein aggregates 
as the protein is concentrated at temperatures above the expected solubility line for the 
P23V single mutant (James et al., 2015). These aggregates have an inverted 
temperature dependence of the solubility line. Once the protein aggregates begin to 
form, the concentration of protein monomers in solution decreases over time (6-24 
hours).  After this period of time, crystal formation on the surface of the aggregates is 
observed (figure 5.9). There are no crystals formed in the bulk solution. The monomer 
concentration in the supernatant is sufficiently high after the aggregate formation is 
complete to allow crystals to form, if we compare the solution conditions to those 
where crystallization of the R58H single mutant occurs (Pande et al., 2001). 
 
 
 
 
 
Figure 5.9: Phase contrast microscopy image of P23VR58H protein aggregates encased in protein 
crystals. Inset shows polarization microscopy image of the same mutant confirming the crystalline 
nature of the protein surface structures, taken from (James et al., 2015).    
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When we attempt to measure the solubility line for this double mutant, we find that the 
crystals and aggregates co-exist with the protein monomers in solution. Hence, the 
measured solubility line is the equilibrium established between solid (crystal + 
aggregates) and liquid (protein monomers). This ‘equilibrium solubility line’ occurs at 
concentrations between those expected for the two individual single mutants as shown 
in figure 5.10 (James et al., 2015). The phase behaviour of the double mutant appears 
to be controlled by the kinetics of the crystallization process. The relative 
concentrations of the solid condensed phases i.e. crystals or aggregates formed are 
defined by the phase boundaries of the initial single mutants and the rate at which 
these condensed phases form (James et al., 2015).  
The position of the solubility line shifts depending on the temperature at which initial 
aggregate formation occurs. As shown in figure 5.11, a greater amount of aggregation 
occurs at temperatures higher than 25°C which shifts the solubility line to higher 
concentrations, closer to the solubility line for P23V single mutant with inverted 
solubility. When lesser aggregation occurs at lower temperatures, increasing numbers 
of crystals are formed and the solubility line moves to lower concentrations, closer to 
the solubility line for the R58H single mutant with normal solubility (James et al., 
2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Phase diagram showing equilibrium solubility line for the co-existing aggregates and 
crystals with the P23VR58H protein monomers, taken from (James et al., 2015). Data for the single 
mutants of HGD are taken from (Pande et al., 2000) and (Pande et al., 2005).   
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Figure 5.11: Shifts in the solubility line depending on the temperature at which initial aggregate/crystal 
formation occurs (James et al., 2015). 
5.3.2.1 Aggregation and crystallization in the P23VR58H double mutant   
The solubility line for the P23VR58H double mutant represents the equilibrium 
between three co-existing protein phases; monomers, aggregates and crystals. Given 
this complexity, this ‘equilibrium solubility line’ can only be used for a qualitative 
analysis. The most interesting observation from the microscopy experiments reveals 
that both crystals and aggregates co-exist with protein monomers in solution (figure 
5.9). The formation of crystals was confirmed by polarization microscopy (figure 5.9).  
According to basic thermodynamic principles, crystals should have the lowest free 
energy and form the most stable solid phase. However, our experiments suggest that 
amorphous aggregates formed by the P23VR58H double mutant are as 
thermodynamically stable as the crystals formed by this same mutant (James et al., 
2015). The solubility boundary for the P23VR58H double mutant is established from 
the initial condensed phase that forms at a particular temperature and there is no 
change in the position of the phase boundary once initial aggregate formation has 
occurred and has been established over a few days. Nonetheless, the solubility 
boundary can be shifted to lower concentrations by decreasing the temperature at 
which initial aggregate formation occurs, thereby decreasing the concentration of 
aggregated material in the solid condensed phase before crystallization begins on the 
surface of the aggregated material as shown in figure 5.11.  Higher temperatures result 
in a greater number of aggregates formed (thereby sequestering a greater proportion of 
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the protein available in solution), whereas lower temperatures suppress aggregate 
formation and allows greater numbers of crystals to form, resulting in phase 
boundaries shifting to lower concentrations approaching the phase boundary of R58H 
single mutant as shown in figure 5.11 (James et al., 2015). Crystallization does not 
occur in the bulk of the protein solution; however, nucleation leading to crystallization 
appears to occur heterogeneously on the surface of these pre-formed amorphous 
aggregates. This sequence of events is possible because crystallization in the R58H 
mutant is delayed, and allows a range of concentrations to be reached where the 
aggregation process can precede crystallization when the solution conditions favour 
this. In this way, the kinetics of the crystallization process due to the R58H substitution 
drives the phase behaviour of the double mutant. Therefore the rate of formation of 
each condensed phase affects the position of the phase boundary for the P23VR58H 
mutant protein.  
5.3.3 Kinetics of Aggregate Growth 
The aggregation for the P23VR58H double mutant at a given concentration begins in a 
monomeric protein solution, devoid of aggregates, incubated at temperatures above the 
phase boundary for the P23V single mutant. The morphology of the aggregates formed 
is very unusual. The aggregates are very large and spherical, both for the single and 
double mutant proteins (figure 5.12 and figure 5.13). To probe the growth of these 
aggregated particles, we took time resolved images during the growth of the 
aggregates, up to and beyond the formation of crystals on the surface of the particles. 
Given the diffraction limit of optical microscopy, only particles of 1μm and larger 
were measured.  
The growth profile for the P23VR58H double mutant protein aggregates show 
amorphous aggregates that grow as three dimensional spherical structures as shown in 
figure 5.12. We track this growth at regular time points after they reach an initial size 
of 1μm, until there is no further increase in the diameter of the particles. After this 
growth is complete, crystal growth occurs on the surface of the pre-formed aggregates. 
The different growth stages of P23VR58H double mutant aggregate for a protein 
concentration of 10 mg.ml
-1 
are as displayed in figure 5.12. These aggregates were 
grown from monomeric protein solution to which 20mM DTT (Dithiothreitol) was 
added prior to inducing aggregation by heating to 30°C (to suppress disulfide linked 
dimer formation). For these solution conditions, at time t ꞊ 127min, the initial clusters 
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with a size of 5.7μm appeared followed by rapid growth into large spherical 
amorphous aggregates with a size of 42.3μm at time t ꞊ 489 minutes, which doesn’t 
increase any further up to 1439 minutes. Crystallization on the surface of the protein 
aggregates only occurs after the aggregates have stopped growing beyond the time 
point of t ꞊ 489 min. This suggests that the aggregation and crystallization processes 
occur independently and that the growth of the aggregate is not halted by the onset of 
crystallization.  
 
 
 
 
 
 
 
Figure 5.12: Growth of P23VR58H aggregates monitored over time at 30°C using phase contrast (a-g) 
and polarization microscopy (h). Each panel indicates a different time point:  127 min (a), 193 min (b), 
282min (c), 332 min (d), 383 min (e), 489 min (f) and 1439 min (g and h). Polarization microscopy 
image indicates optical birefringence, indicative of ordered structures, most probably due to 
crystallization on the surface of the P23VR58H protein aggregate beyond 489 mins.   
To confirm this, we have also compared the growth of the P23VR58H double mutant 
aggregates with the growth of P23V single mutant aggregates. Both the double and 
single mutants give rise to the spherical aggregates which are similar in their 
morphological appearances and both exhibit inverted solubility. As shown in figure 
5.13, the P23V aggregates resemble the P23VR58H double mutant aggregates except 
for the absence of crystallization on the surface of pre-formed aggregates as confirmed 
by the polarization microscopy image (figure 5.13(e and h)). This suggests that the 
crystallization behaviour on the surface of P23VR58H aggregates is only present due 
to the R58H substitution in the double mutant protein (James et al., 2015). The P23V 
single mutant is known to form both crystals or aggregates  and the solubility/liquidus 
lines for both condensed phases overlap (McManus et al., 2007).  
 
a b c d 
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Figure 5.13: Growth of the P23V aggregate monitored over time at 30°C from a solution at 10 mg/ml in 
0.1M sodium phosphate buffer using phase contrast (a-g) and polarization microscopy (h). 187 min (a), 
272 min (b), 434min (c), 1204 min (d and e), 1336 min (g and h). Polarization microscopy image (e and 
h) confirms absence of surface crystallization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Graphical representation for the sigmoidal growth pattern of P23VR58H double mutant 
aggregates.    
The evolution of the growth of amorphous aggregates at different concentrations of the 
double mutant protein P23VR58H and also for the single mutant protein P23V at 10 
mg.ml
-1
 is shown in figure 5.14. 
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The data indicates that, as for most protein aggregation phenomena, the growth of 
protein aggregates follow a sigmoidal curve (Frieden & Goddette, 1983, Flyvbjerg et 
al., 1996, Fink, 2006, Kamihira et al., 2000). While the growth kinetics of amyloid 
forming protein aggregates have been studied in great detail (Lomakin, Chung, et al., 
1996, DuBay et al., 2004, Cohen et al., 2013, Knowles et al., 2007), the growth of 
amorphous protein aggregates has received far less attention (Stranks et al., 2009). As 
such, there are fewer kinetic models describing the growth process for amorphous 
protein aggregation. Furthermore, amorphous protein aggregates usually form fractal 
structures (Aymard et al., 1997), whereas the structures formed here are unusually 
spherical. Therefore detailed information about the aggregation pathway that can be 
extracted from our initial experimental measurements is somewhat limited.  
If we follow the growth of the aggregates, there is a period of time for which we do not 
see particles (although we know that growth is occurring during this time period). This 
is not a lag phase, but rather a period of time for which we do not have data. Once 
particles of 1μm in size appear, there is an exponential increase in the size of the 
aggregates and a subsequent plateau where the growth ceases and the aggregates 
remain at the same size. Once the aggregate growth has terminated, for all 
concentrations of protein the maximum diameter of the spherical aggregates was 40-
50μm. Depending on the initial monomer protein concentration, there is a shift in the 
time it takes to see the appearance of 1μm sized particles. This concentration 
dependence on the initial growth of aggregates is consistent with a diffusion limited 
mechanism of particle growth (Witten & Sander, 1983). 
5.3.3.1 Rate of formation of initial clusters  
We define the second stage of growth to be the formation of 1 micron-sized particles 
with size ranging from 1-5 μm. This is initiated in a supersaturated solution, at 
temperatures above the phase boundary for the mutant (≥ 30°C) (figure 5.10). We 
speculate that protein monomers of the double mutant protein, P23VR58H, begin to 
form small nuclei due to concentration fluctuations (via diffusion) and that by a 
process of monomer addition grow into larger clusters over time. The complexity of 
studying nucleation event arises from the fact that nuclei typically comprises of 100-
1000 atoms which are inaccessible to current experimental methods (Schüth et al., 
2001). A few microscopic techniques allow detection without distinction of the sub-
microscopic nuclei (Yau & Vekilov, 2001). The formation of nuclei from a metastable 
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solution is referred to as nucleation and represents a first-order phase transition. The 
growth stage leading up to the formation of aggregates is governed by diffusion of 
protein monomers and addition of growth units to the surface of the existing critical 
nuclei (Stranks et al., 2009).  
The rate of formation of clusters with a size of 1μm was investigated for the different 
P23VR58H double mutant concentrations (figure 5.15). This is taken as the time 
between the change in temperature to 30°C and the point at which the first particles of 
1μm in size appear. What is particularly interesting is that although only single 
particles are followed throughout the growth process, all of the particles in a particular 
solution grow at the same rate. There is remarkable homogeneity in the distribution of 
particle sizes throughout the aggregating solution. With increasing concentration, the 
time taken for a 1μm sized particle to appear decreases (again consistent with a 
diffusion driven nucleation mechanism). At lower protein concentrations, it takes 
longer to achieve thermodynamic stability by the formation of these micron-sized 
clusters and this is not surprising. As the protein concentration is lowered, there are 
fewer protein monomers randomly moving around in the solution volume to add onto 
the surface of the nuclei. Thus, it takes longer to both form clusters at lower protein 
concentrations and longer for the aggregates to grow (figure 5.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Plot of initial lag phase time vs. protein concentration for the P23VR58H double mutant 
clusters.  
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5.3.3.3 Growth rate for the formation of large spherical aggregates in the 
transitional phase 
Once the formation of clusters is initiated in solution, they may act as centres for 
growth leading to the formation of large spherical aggregates whose growth follows a 
sigmoidal pattern. Recently, a Gompertz function was utilized to understand the 
particle growth in kinetic studies of protein aggregation (Skrdla, 2012). This function 
has long been described to study population mortality (Kozusko & Bajzer, 2003) and 
malignant tumour formation (Laird, 1964). We have utilized the equation for 
Gompertz function given by 5.1 to fit the growth curve for the P23VR58H double 
mutant aggregate, 
                                           
  cxxkeaey
                                  5.1 
where a is a point on the sigmoidal curve where it intersects the horizontal asymptote 
(the maximum aggregate size), xc , is the mid-point of the exponential phase of 
aggregate growth and k is the particle growth rate. 
Concentration 
of P23VR58H
 
(1) or P23V 
(2) 
a (μm) xC (min) k (min
-1
) 
(1) 10 mg.ml
-1 43.34 
44.37 
199.81 
206.76 
0.01 
0.01 
(1) 7.5 mg.ml
-1 49.4 
45.04 
386.65 
376.08 
0.005 
0.0075 
(1) 5 mg.ml
-1 39.26 
40.33 
420.93 
423.94 
0.004 
0.004 
(2) 10mg.ml
-1
 37.39 214.79 0.0066 
 
Table 5.1: Values of the parameters a (maximum particle size), xc(mid-point of particle growth) and k 
(growth rate) extracted from the Gompertz fit to the growth curve for the various concentrations of the 
P23VR58H double mutant and for P23V single mutant at 10 mg.ml
-1
.  
A Gompertz fit to the experimental data provides values for a, xc and k at each protein 
concentration for both the P23VR58H double mutant protein and the P23V single 
mutant (table 5.1). The growth rates plotted for the different P23VR58H double mutant 
concentrations give rise to a slope with a linear relationship established between 
growth rate and protein concentration (figure 5.16). 
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This linear relationship between growth rate (k) and P23VR58H protein concentration 
suggests that the P23VR58H aggregates follow a first-order growth process. The 
concentration dependence on the growth rate for the P23VR58H double mutant 
follows a linear regression given by equation 5.2, 
                                   )(48.81896.1 ck                                           5.2 
This indicates that the growth rate for the P23VR58H aggregates depend only on the 
initial concentration of the P23VR58H protein solution prior to the temperature change 
that leads to aggregation. This is consistent with diffusion driven growth mechanism 
where concentration is the major driving factor in aggregate growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: Plot of growth rate vs. protein concentration for the P23VR58H double mutant 
aggregates. 
5.3.3.4 Termination of aggregate growth in the plateau phase 
The exponential growth phase ceases once the aggregates attain a maximum diameter 
in the range between 40-50 μm for all the concentrations studied in here. This is 
consistent with diffusion limited aggregation i.e. as time elapses there are fewer 
protein monomers available to add on to the surface of the existing aggregate. Hence, 
beyond a certain point of time for each concentration the growth of these large 
spherical aggregates enter a plateau phase. One such aggregation studies on α-
synuclein aggregates shows a similar plateau phase (Fink, 2006). 
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5.3.3.5 Crystallization on the surface of the amorphous aggregate 
The P23VR58H aggregate growth is terminated due to the diffusion limited 
availability of protein monomers to add onto the surface of existing aggregates. 
However, the concentration of protein monomers in the solution is still sufficiently 
high enough to allow protein crystal formation on the surface of these pre-formed 
spherical amorphous aggregates as shown in figure 5.12(h). Comparative studies of the 
P23VR58H double mutant with the P23V single mutant suggests that crystallization on 
the surface of P23VR58H aggregate occur independent of the diffusion limited 
aggregation phenomena and that the processes are not coupled (i.e. crystallization does 
not stop aggregate growth).  
5.4 Conclusion 
The third double mutant P23VR58H protein incorporating the P23V substitution 
associated with inverted solubility and the R58H substitution associated with 
crystallization are soluble following extraction and purification procedures, they also 
maintain their native conformation post mutagenesis confirmed by circular dichroism 
spectroscopy. The P23VR58H double mutant primarily forms aggregates when 
concentrated at temperatures above the solubility line for the P23V single mutant and 
crystallization occurs heterogeneously with time on the surface of these pre-formed 
aggregates which is highly temperature dependent. The solubility line which is the 
equilibrium between protein monomers and protein solid phase (crystals + aggregates) 
appears between the solubility lines for the two individual single mutants. However, 
when the temperature for the formation of initial aggregate material is lowered the 
solubility line shifts to lower concentrations approaching the normal solubility line for 
the R58H single mutant. The P23VR58H double mutant gives rise to large three 
dimensional spherical aggregates whose nucleation, growth and termination of growth 
is consistent with a diffusion limited aggregation mechanism. The growth of these 
aggregates follow a sigmoidal pattern and using a Gompertz function to fit the growth 
curve, the growth rate is found to have a linear dependence on protein concentration 
suggesting a first-order mechanism for the growth of P23VR58H aggregates.      
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Summary and final conclusions 
This work focuses on the phase diagrams for double mutants of human γD-crystallin 
(HGD). The three double mutants of HGD used in this study are P23VR36S, 
P23TR36S and P23VR58H. All the three double mutants are soluble following 
extraction and purification procedures. They also maintain their native structure upon 
mutagenesis as confirmed by spectroscopic techniques.  
The first double mutant used in our study, P23VR36S, forms a solid condensed phase 
(crystals) that resemble one of the single parent mutants (R36S). Furthermore, the 
liquidus line for the P23VR36S double mutant overlaps with the liquidus line for the 
R36S single mutant. The R36S single mutant forms a new crystal contact and analysis 
of the microscopy images and liquidus lines suggests that this contact has been 
preserved in the double mutant. The behaviour of the P23VR36S double mutant by 
itself would more likely reflect upon the crystal contact formed by the R36S 
substitution that dominates the behaviour of the double mutant. The kinetics of the 
R36S crystallization is fast and therefore, it is not possible to explore the higher 
concentration region of the phase diagram where the solubility line due to the P23V 
aggregates occur. The most interesting observation for the second double mutant, 
P23TR36S, is the formation of crystals with two different solubility behaviours: one, a 
rod-shaped crystal with normal solubility and second, a rhombic-shaped crystal with 
inverted solubility. For the point at which the individual liquidus lines for each single 
mutant overlaps, we get co-existence of the two crystal forms. To understand this 
polymorphism, X-ray crystallographic analysis was performed on both crystal types of 
the double mutant. Initial crystallographic analysis suggests the formation of a new 
molecular contact around position 23 of the double mutant responsible for the 
formation of rhombic-shaped crystals with inverted solubility. 
The phase diagram for the third double mutant, P23VR58H, suggests that the solubility 
lines formed due to equilibrium between protein monomers and protein solid phase 
(crystals + aggregates) may be kinetically controlled by influencing the temperature 
for initial aggregate formation. As the temperature for the formation of initial 
aggregates is lowered, the solubility line shifts to lower concentrations approaching the 
normal solubility line for the R58H single mutant. The double mutant forms large 
amorphous aggregates via nucleation and growth which is consistent with diffusion 
limited aggregation mechanism. The growth curve is sigmoidal and follows a first-
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order growth mechanism. Although the double mutant primarily forms large spherical 
aggregates, the concentration of protein monomers is sufficiently high enough to allow 
crystallization on the surface of these pre-formed aggregates. The table shown below 
summarizes the properties exhibited by all the three double mutant proteins used in 
this study.  
Double mutant 
protein 
Nature of condensed phase Solubility type 
P23VR36S Protein crystals formed Normal solubility 
 
P23TR36S 
 
Rhombic-shaped crystals formed Inverted solubility 
Rod-shaped crystals formed Normal solubility 
P23VR58H 
Co-existence of protein aggregates 
and crystals observed. 
                Normal solubility 
These observations suggest that self-assembly of proteins is controlled by a number of 
factors ranging from the formation of new crystal contacts, the orientation of protein 
molecules that are in close proximity with each other along with solution conditions 
that influence directional anisotropic interactions and dictate the formation of protein 
condensed phases. This has been qualitatively and semi-quantitatively confirmed in the 
explored double mutant proteins. 
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